



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Giampaolo Bianchini**
E-mail Bianchini.giampaolo@hsr.it
Fiscal code BNCGPL71E24A794H
Nationality Italian
Date of birth 24 May 1971
Gender Male

Work experience

Dates	11/2023 to present
Occupation or position held	Associate professor for Medical Oncology
Main activities and responsibilities	Teaching oncology at Degree Course in Medicine and Surgery
Name and address of employer	Vita-Salute San Raffaele University, Via Olgettina 58, 20132, Milan, Italy
Dates	2/2019 to present
Occupation or position held	Head of Breast Cancer Group
Name and address of employer	Ospedale San Raffaele, Department of Medical Oncology, Via Olgettina 60, 20132, Milan, Italy
Dates	4/2017 to present
Occupation or position held	Head of clinical translational and immunotherapy research
Main activities and responsibilities	Clinical translational researches and immunotherapy research
Name and address of employer	Ospedale San Raffaele, Department of Medical Oncology, Via Olgettina 60, 20132, Milan, Italy
Dates	3/2017 to 11/2023
Occupation or position held	Assistant professor for the integrated course of oncology (nontenured, non-salaried)
Main activities and responsibilities	Teaching oncology at Degree Course in Medicine and Surgery
Name and address of employer	Vita-Salute San Raffaele University, Via Olgettina 58, 20132, Milan, Italy
Dates	4/2011 to 11/2023
Occupation or position held	Physician scientist
Main activities and responsibilities	Clinical activity as medical oncologist, clinical and translational researches
Name and address of employer	Ospedale San Raffaele, Department of Medical Oncology, Via Olgettina 60, 20132, Milan, Italy
Dates	4/2015 – 5/2015
Occupation or position held	Visiting Professor
Main activities and responsibilities	Translational research
Name and address of employer	Yale Cancer Center, New Haven, USA
Dates	12/2008 – 12/2009
Occupation or position held	Visiting Scientist
Main activities and responsibilities	Clinical and translational researches
Name and address of employer	University of Texas, M. D. Anderson Cancer Center, Breast Medical Oncology Department, Houston, Texas

Dates	9/2007 - 12/2007
Occupation or position held	Guest research fellow
Main activities and responsibilities	Translational researches
Name and address of employer	National Cancer Institute, Biometric Research Branch, Division of Cancer Treatment and Diagnosis, Bethesda, MD, USA
Dates	1/2005 – 3/2011
Occupation or position held	Consultant in Medical Oncology
Main activities and responsibilities	Clinical activity, clinical and translational researches
Name and address of employer	Fondazione IRCCS - Istituto Nazionale dei Tumori, Division of Medical Oncology, Milan, Italy

Education and training

Dates	4/11/2004
Title of qualification awarded	Board Certification in Medical Oncology (score: 70/70 with honors)
Principal subjects/occupational skills covered	Residency in Medical Oncology
Name and type of organisation providing education and training	University of Milan, School of Medicine, c/o Istituto Nazionale dei Tumori, Milan, Italy
Level in national or international classification	Board Certification in Medical Oncology
Dates	2001
Title of qualification awarded	State Board Examination for Medical Licensing in European Community
Name and type of organisation providing education and training	University of Milan, School of Medicine, Milan, Italy
Level in national or international classification	State Board Examination for Medical Licensing in European Community
Dates	7/20/2000
Title of qualification awarded	M.D. Degree (score: 110/110 with honors)
Principal subjects/occupational skills covered	Medicine Degree
Name and type of organisation providing education and training	University of Milan-Bicocca, School of Medicine, Milan, Italy
Level in national or international classification	M.D. Degree
Dates	1991
Title of qualification awarded	High school degree (score: 60/60)
Name and type of organisation providing education and training	Istituto Tecnico Industriale di Stato, Pietro Paleocopa

Personal skills and competences

ABILITAZIONE SCIENTIFICA NAZIONALE

Settore concorsuale 06/D3, fascia II BANDO D.D. 1532/2016 SETTORE CONCORSALE 06/D3
 Conseguimento dell'abilitazione nazionale ai sensi dell'art. 16 della Legge 240/2010 per il settore concorsuale 06/D3, fascia II VALIDO DAL 28/03/2018

Mother tongue(s) **Italian**

Other language(s)

Self-assessment

European level (*)

English

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
Proficient user (C1)	Proficient user (C1)	Proficient user (C1)	Proficient user (C1)	Proficient user (C1)

(*) [Common European Framework of Reference for Languages](http://europass.cedefop.europa.eu)

Publications

- 2004** Fusi A, Procopio G, Della Torre S, Ricotta R, **Bianchini G**, Salvioni R, Ferrari L, Martinetti A, Savelli G, Villa S, Bajetta E.
TREATMENT OPTIONS IN HORMONE-REFRACTORY METASTATIC PROSTATE CARCINOMA
Tumori (2004) 90(6): 535-46
- 2008** Gianni L, **Bianchini G**, Mariani G.
STATE OF THE ART OF ADJUVANT THERAPY
Eur J Cancer Supplements (2008) 6 (7): 27-30
- Bianchini G**, Gianni L.
INTRODUCING NEW MOLECULAR TECHNOLOGIES INTO ROUTINE CLINICAL CANCER CARE: IS THERE AN IMPACT ON THE TREATMENT OF BREAST CANCER?
Ann Oncol. (2008);19 Suppl 7: vii177-83
- 2009** Iwamoto T, Coutant C, **Bianchini G**, Puztai L.
MOLECULAR HETEROGENEITY OF ESTROGEN RECEPTOR-POSITIVE BREAST CANCER EXPLAINS VARIABLE AND CONTRADICTORY RESULTS OF RANDOMIZED ADJUVANT CHEMOTHERAPY TRIALS IN BREAST CANCER
American Journal of Hematology/Oncology. August 2009
- 2010** **Bianchini G**, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Puztai L.
MOLECULAR ANATOMY OF BREAST CANCER STROMA AND ITS PROGNOSTIC VALUE IN ESTROGEN RECEPTOR-POSITIVE AND -NEGATIVE CANCERS
J Clin Oncol (2010) 28:4316-23
- Kelly CM, Krishnamurthy S, **Bianchini G**, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Puztai L.
UTILITY OF ONCOTYPE DX RISK ESTIMATES IN CLINICALLY INTERMEDIATE RISK HORMONE RECEPTOR-POSITIVE, HER2-NORMAL, GRADE II, LYMPH NODE-NEGATIVE BREAST CANCERS
Cancer (2010) 116:5161-7
- Bianchini G**, Iwamoto T, Qi Y, Coutant C, Shiang C, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WK, Gianni L, Puztai L.
PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF DISTINCT KINASE EXPRESSION PATTERNS IN DIFFERENT SUBTYPES OF BREAST CANCER
Cancer Res (2010) 70:8852-62
- Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, **Bianchini G**, Yang CY, Yong Li, Xinqun Li, Chun-Te Chen, Gordon B. Mills, Gabriel N. Hortobagyi, John Mendelsohn, Mien-Chie Hung, and Zhen Fan
RECOMBINANT HUMAN ERYTHROPOIETIN ANTAGONIZES TRASTUZUMAB TREATMENT OF BREAST CANCER CELLS VIA JAK2-MEDIATED ACTIVATION OF SRC AND INACTIVATION OF PTEN
Cancer Cell (2010) 18:423-35
- Iwamoto T, **Bianchini G**, Booser D, Qi Y, Coutant C, Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes F, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Puztai L.
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER
J Natl Cancer Inst 2010 Dec 29
- 2011** Iwamoto T, **Bianchini G**, Qi Y, Cristofanilli M, Lucci A, Woodward W, Reuben JM, Matsuoka J, Hortobagyi GN, Robertson F, Symmans WF, Puztai L, Ueno NT.
DIFFERENT GENE EXPRESSION ARE ASSOCIATED WITH THE DIFFERENT MOLECULAR SUBTYPES OF INFLAMMATORY BREAST CANCER
Breast Cancer Res Treat (2011);125(3):785-95
- Coutant C, Rouzier R, Qi Y, Lehmann-Che J, **Bianchini G**, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de The H, Puztai L.
CLINICAL SUBTYPE-DERIVED P53 GENE SIGNATURE IS PREDICTIVE OF PROGNOSIS AND RESPONSE TO CHEMOTHERAPY IN ER-POSITIVE BUT NOT IN ER-NEGATIVE BREAST CANCERS
Clin Cancer Res (2011) 17:2591-601

- Iwamoto T, Lee JS, **Bianchini G**, Hubbard RE, Young E, Matsuoka J, Kim SB, Symmans WF, Hortobagyi GN, Puztai L
FIRST GENERATION PROGNOSTIC GENE SIGNATURES FOR BREAST CANCER PREDICT BOTH SURVIVAL AND CHEMOTHERAPY SENSITIVITY AND IDENTIFY OVERLAPPING PATIENT POPULATIONS
 Breast Cancer Res Treat. (2011);130(1):155-64
- Bianchini G**, Gianni L.
SURROGATE MARKERS FOR TARGETED THERAPY-BASED TREATMENT ACTIVITY AND EFFICACY
 J Natl Cancer Inst Monogr. (2011); (43): 91-4
- 2012 Dutta B, Puztai L, Qi Y, André F, Lazar V, **Bianchini G**, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balázs G
A NETWORK-BASED, INTEGRATIVE STUDY TO IDENTIFY CORE BIOLOGICAL PATHWAYS THAT DRIVE BREAST CANCER CLINICAL SUBTYPES
 Br J Cancer. (2012);106(6):1107-16.
- Pietrantonio F, Biondani P, de Braud F, Pellegrinelli A, **Bianchini G**, Perrone F, Formisano B, Di Bartolomeo M.
BAX EXPRESSION IS PREDICTIVE OF FAVORABLE CLINICAL OUTCOME IN CHEMONAIVE ADVANCED GASTRIC CANCER PATIENTS TREATED WITH CAPECITABINE, OXALIPLATIN, AND IRINOTECAN REGIMEN
 Transl Oncol. 2012; 5(3):155-159.
- 2013 **Bianchini G**, Gianni L.
HER2-DIRECTED T-CELL RECEPTOR-MIMICKING ANTIBODY: A "ME TOO" OR AN EXAMPLE OF NOVEL ANTITUMOR AGGRESSIVE MIMICRY?
 J Natl Cancer Inst. (2013);105(3):161-3
- Kelly CM, Symmans WF, Andreopoulou E, **Bianchini G**
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION
 Oncologist. (2013);18(4): e11-2
- Bianchini G***, Puztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Muller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Angelica F, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
PROLIFERATION AND ESTROGEN SIGNALING CAN DISTINGUISH PATIENTS AT RISK FOR EARLY VERSUS LATE RELAPSE AMONG ESTROGEN RECEPTOR POSITIVE BREAST CANCERS
 Breast Cancer Research (2013) 15: R86.
 *(corresponding author)
- Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Bottai G, Stampfer M, Andre F, Turner NC, Symmans WF, Hortobagyi GN, Puztai L, **Bianchini G**
DNA REPAIR GENE PATTERNS AS PROGNOSTIC AND PREDICTIVE FACTORS IN MOLECULAR BREAST CANCER SUBTYPES
 Oncologist (2013); 18(10): 1063 – 1073
- Bianchini G**, Gianni L
AN UNMET NEED: TAILORING EXTENDED ADJUVANT ENDOCRINE THERAPY
 British Journal of Cancer (2013), 1–4
- 2014 Callari M, Lembo A, **Bianchini G**, Musella V, Cappelletti V, Gianni L, Daidone MG, Provero P
ACCURATE DATA PROCESSING IMPROVES THE RELIABILITY OF AFFYMETRIX GENE EXPRESSION PROFILES FROM FFPE SAMPLES
 PLoS One (2014) 9(1): e86511
- Bianchini G**, Gianni L
THE IMMUNE SYSTEM AND RESPONSE TO HER2-TARGETED THERAPY IN BREAST CANCER
 The Lancet Oncology (2014) 15: e58-e68

- Prat A, **Bianchini G**, Thomas M, Belousov A, Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhov M, Bermejo B, Zambetti M, Vazquez V, Gianni L, Baselga J
RESEARCH-BASED PAM50 SUBTYPE PREDICTOR IDENTIFIES HIGHER RESPONSES AND IMPROVED SURVIVAL OUTCOMES IN HER2-POSITIVE BREAST CANCER IN THE NOAH STUDY
 Clin Cancer Res (2014) 20:511-21, 2014
- Gyorffy B, Bottai G, Lehmann-Che J, Keri G, Orfi L, Iwamoto T, Desmedt C, **Bianchini G**, Turner NC, de The H, Andre F, Sotiriou C, Hortobagyi GN, Di Leo A, Puztai L, Santarpia L
TP53 MUTATION-CORRELATED GENES PREDICT THE RISK OF TUMOR RELAPSE AND IDENTIFY MPS1 AS A POTENTIAL THERAPEUTIC KINASE IN TP53-MUTATED BREAST CANCERS
 Mol Oncol, (2014)
- Karn T, Sängler N, Ruckhäberle E, **Bianchini G**, Müller V, Rody A, Solomayer EF, Fehm T, Holtrich U, Becker S
OPG AND PGR SHOW SIMILAR COHORT SPECIFIC EFFECTS AS PROGNOSTIC FACTORS IN ER POSITIVE BREAST CANCER
 Mol Oncol. (2014)
- 2015** Generali D, Fox SB, Cristofanilli M, **Bianchini G**, Zambelli A, Hatzis C, Barberis M, Tarricone R, Bottini A, Rossi C, Tringali M (2015)
NEOADJUVANT MODEL IN CANCER TREATMENT: FROM CLINICAL OPPORTUNITY TO HEALTH-CARE UTILITY
 J Natl Cancer Inst Monogr (2015) (51): 1-3
- Musella V, Callari M, Di Buduo E, Scuro M, Dugo M, Miodini P, **Bianchini G**, Paolini B, Gianni L, Daidone MG, Cappelletti V
USE OF FORMALIN-FIXED PARAFFIN-EMBEDDED SAMPLES FOR GENE EXPRESSION STUDIES IN BREAST CANCER PATIENTS
 PLoS One (2015) 10(4): e0123194
- Cottini F, Hideshima T, Suzuki R, Tai YT, **Bianchini G**, Richardson PG, Anderson KC, Tonon G
SYNTHETIC LETHAL APPROACHES EXPLOITING DNA DAMAGE IN AGGRESSIVE MYELOMA
 Cancer Discov (2015) 5(9): 972-87
- Bianchini G**, Puztai L, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Galeota E, Magazzù D, Rodríguez J, Oh D-Y, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L
IMMUNE MODULATION OF PATHOLOGIC COMPLETE RESPONSE AFTER NEOADJUVANT HER2-DIRECTED THERAPIES IN THE NEOSPHERE TRIAL
 Annals of Oncology (2015) 26(12): 2429-36
- Schneider D, **Bianchini G**, Horgan D, Michiels S, Witjes W, Hills R, Plun-Favreau J, Brand A, Lawler M
ESTABLISHING THE EVIDENCE BAR FOR MOLECULAR DIAGNOSTICS IN PERSONALISED CANCER CARE
 Public Health Genomics (2015) 18(6): 349-58
- 2016** Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, **Bianchini G***
SUBTYPE SPECIFIC METAGENE-BASED PREDICTION OF OUTCOME AFTER NEOADJUVANT AND ADJUVANT TREATMENT IN BREAST CANCER
 Clinical Cancer Research (2016) 22(2): 337-45
 * (corresponding author)
- Safonov A, Wang S, Gross CP, Agarwal D, **Bianchini G**, Puztai L, Hatzis C
ASSESSING COST-UTILITY OF PREDICTIVE BIOMARKERS IN ONCOLOGY: A STREAMLINED APPROACH
 Breast Cancer Res Treat (2016) 155(2): 223-234
- Puztai L, Karn T, Safonov A, Abu-Khalaf MM, **Bianchini G**
NEW STRATEGIES IN BREAST CANCER: IMMUNOTHERAPY
 Clin Cancer Res (2016) 22(9): 2105-10

	Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L TRIPLE-NEGATIVE BREAST CANCER: CHALLENGES AND OPPORTUNITIES OF A HETEROGENEOUS DISEASE Nat Rev Clin Oncol (2016);13(11):674-690. Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T, Hayashi N, Yokoyama K, Oshitani R, Terao M, Morioka T, Tsuda B, Okamura T, Saito Y, Suzuki Y, Tokuda Y COMPARISON OF TUMOUR-INFILTRATING LYMPHOCYTES BETWEEN PRIMARY AND METASTATIC TUMOURS IN BREAST CANCER PATIENTS Cancer Sci (2016) 107(12): 1730-1735
2017	Canova S, Cicchiello F, Agustoni F, Bianchini G, Abbate MI, Bidoli P, Cortinovis DL GEMCITABINE-INDUCED THROMBOCYTOSIS AS A POTENTIAL PREDICTIVE FACTOR IN NON-SMALL CELL LUNG CANCER: ANALYSIS OF 318 PATIENTS Tumori (2017) 103(2): 143-147 Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szabo T, Eng-Wong J, Amler LC, Valagussa P, Gianni L BIOMARKER ANALYSIS OF THE NEOSPHERE STUDY: PERTUZUMAB, TRASTUZUMAB, AND DOCETAXEL VERSUS TRASTUZUMAB PLUS DOCETAXEL, PERTUZUMAB PLUS TRASTUZUMAB, OR PERTUZUMAB PLUS DOCETAXEL FOR THE NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER Breast Cancer Res (2017) 19(1): 16 Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Gianni L, Koch JP, Tyson DR, Sanchez V, Rexer BN, Sanders M, Zhao Z, Stricker T, Arteaga CL EXTRACELLULAR MATRIX/INTEGRIN SIGNALING PROMOTES RESISTANCE TO COMBINED INHIBITION OF HER2 AND PI3K IN HER2+ BREAST CANCER Cancer Res (2017) 77(12): 3280-3292 Safonov A, Jiang T, Bianchini G, Györfy B, Karn T, Hatzis C, Pusztai L IMMUNE GENE EXPRESSION IS ASSOCIATED WITH GENOMIC ABERRATIONS IN BREAST CANCER Cancer Res (2017) 77(12): 3317-3324 Karn T, Jiang T, Hatzis C, Sängler N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L ASSOCIATION BETWEEN GENOMIC METRICS AND IMMUNE INFILTRATION IN TRIPLE-NEGATIVE BREAST CANCER JAMA Oncology (2017) 3:1707-1711
2018	Kochi M, Iwamoto T, Niikura N, Bianchini G, Masuda S, Mizoo T, Nogami T, Shien T, Motoki T, Taira N, Tokuda Y, Doihara H, Matsuoka J, Fujiwara T TUMOUR-INFILTRATING LYMPHOCYTES (TILS)-RELATED GENOMIC SIGNATURE PREDICTS CHEMOTHERAPY RESPONSE IN BREAST CANCER Breast Cancer Res Treat. (2018) 167(1):39-47 Callari M, Dugo M, Miodini P, Veneroni S, Bianchini G, Daidone MG, Cappelletti V (2018) DISSECTING TIME- FROM TUMOR-RELATED GENE EXPRESSION VARIABILITY IN BILATERAL BREAST CANCER. Int J Mol Sci (2018);19. Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, Silber A, Park T, Harigopal M, Pelekanou V, Zhang M, Yan Q, Rimm DL, Bianchini G, Hatzis C, Pusztai L. IMMUNOLOGICAL DIFFERENCES BETWEEN PRIMARY AND METASTATIC BREAST CANCER Ann Oncol. (2018) 29(11):2232-2239
2019	Bianchini G IS TRASTUZUMAB SINGLE AGENT OBSOLETE IN ERALY BREAST CANCER? NO Breast. (2019); 43:142-145

- Ochi T, **Bianchini G**, Ando M, Nozaki F, Kobayashi D, Criscitiello C, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N
PREDICTIVE AND PROGNOSTIC VALUE OF STROMAL TUMOUR-INFILTRATING LYMPHOCYTES BEFORE AND AFTER NEOADJUVANT THERAPY IN TRIPLE NEGATIVE AND HER2-POSITIVE BREAST CANCER
 Eur J Cancer. (2019); 118:41-48
- 2020** Viale, G., L. Licata, L. Sica, S. Zambelli, P. Zucchinelli, A. Rognone, D. Aldrighetti, R. Di Micco, V. Zuber, M. Pasetti, N. Di Muzio, M. Rodighiero, P. Panizza, I. Sassi, G. Petrella, S. Cascinu, O. D. Gentilini, **G. Bianchini**
PERSONALIZED RISK-BENEFIT RATIO ADAPTATION OF BREAST CANCER CARE AT THE EPICENTER OF COVID-19 OUTBREAK
 The Oncologist (2020) 25(7): e1013-e1020.
 (§Corresponding Author)
- 2021** Triulzi TS, **Bianchini GS**, Di Cosimo SS, Pienkowski T, Im Y-H, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng L-M et al:
THE TRAR GENE CLASSIFIER TO PREDICT RESPONSE TO NEOADJUVANT THERAPY IN HER2-POSITIVE AND ER-POSITIVE BREAST CANCER PATIENTS: AN EXPLORATIVE ANALYSIS FROM THE NEOSPHERE TRIAL
 Molecular Oncology (2021)
 (§Co-first author)
- Fodor A, Brombin C, Mangili P, Borroni F, Pasetti M, Tummineri R, Zerbetto F, Longobardi B, Perna L, Dell'Oca, Deantoni, C, Deli Aniko M, Chiara A, Broggi S, Castriconi R, Esposito PG, Slim N, Passoni P, Baroni S, Villa SL, Rancoita PMV; Fiorino C, Del Vecchio A, **Bianchini G**, Gentilini O, Di Serio MS, Di Muzio NG.
IMPACT OF MOLECULAR SUBTYPE ON 1325 EARLY-STAGE BREAST CANCER PATIENTS HOMOGENEously TREATED WITH HYPOFRACTIONATED RADIOTHERAPY WITHOUT BOOST: SHOULD THE INDICATIONS FOR RADIOTHERAPY BE MORE PERSONALIZED?
 The Breast (2021), 55:45-54.
- Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J et al (LUCY Investigators: **Bianchini G**):
CLINICAL EFFECTIVENESS OF OLAPARIB MONOTHERAPY IN GERMLINE BRCA-MUTATED, HER2-NEGATIVE METASTATIC BREAST CANCER IN A REAL-WORLD SETTING: PHASE IIIB LUCY INTERIM ANALYSIS
 European Journal of Cancer (2021), 152:68-77.
- Di Micco R, Santurro L, Gasparri ML, Zuber V, Cisternino G, Baleri S, Morgante M, Rotmensz N, Canevari C, Gallivanone F, Scifo P, Savi A, Magnani P, Neri I, Ferjani N, Venturini E, Losio C, Sassi I, **Bianchini G**, Panizza P, Gianolli L, Gentilini OD
PET/MRI FOR STAGING THE AXILLA IN BREAST CANCER: CURRENT EVIDENCE AND THE RATIONALE FOR SNB VS. PET/MRI TRIALS
 Cancers (2021), 13(14):3571
- Guardia C, **Bianchini G**, Arpi LO, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L et al:
PRECLINICAL AND CLINICAL CHARACTERIZATION OF FIBROBLAST-DERIVED NEUREGULIN-1 ON TRASTUZUMAB AND PERTUZUMAB ACTIVITY IN HER2-POSITIVE BREAST CANCER
 Clin Cancer Res (2021), 27(18):5096-5108
- Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S et al (PERUSE investigators: **Bianchini G**)
FINAL RESULTS FROM THE PERUSE STUDY OF FIRST-LINE PERTUZUMAB PLUS TRASTUZUMAB PLUS A TAXANE FOR HER2-POSITIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER, WITH A MULTIVARIABLE APPROACH TO GUIDE PROGNOSTICATION
 Annals of Oncology (2021), 32(10):1245-1255
- Gasparri ML, Di Micco R, Zuber V, Taghavi K, **Bianchini G**, Bellaminutti S, Meani F, Graffeo R, Candiani M, Mueller MD et al:
OVARIAN RESERVE OF WOMEN WITH AND WITHOUT BRCA PATHOGENIC VARIANTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
 The Breast (2021), 60:155-162.

El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M et al (The International Immuno-Oncology Biomarker Working Group: **Bianchini G**)
THE TALE OF TILS IN BREAST CANCER: A REPORT FROM THE INTERNATIONAL IMMUNO-ONCOLOGY BIOMARKER WORKING GROUP
 Npj Breast Cancer (2021), 7(1):150.

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J et al (OlympiA Investigators: **Bianchini G**)
ADJUVANT OLAPARIB FOR PATIENTS WITH BRCA1- OR BRCA2-MUTATED BREAST CANCER
 New England Journal of Medicine (2021), 384(25):2394-2405

2022 Pálkás HL, Pongor L, Balajti M, Nagy Á, Nagy K, Békési A, Bianchini G, Vértessy BG, Györfy B
PRIMARY FOUNDER MUTATIONS IN THE PRKDC GENE INCREASE TUMOR MUTATION LOAD IN COLORECTAL CANCER
 International Journal of Molecular Sciences (2022), 23(2).

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, **Bianchini G**, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffei I, Valagussa P, Viale G.
PATHOLOGIC COMPLETE RESPONSE (PCR) TO NEOADJUVANT TREATMENT WITH OR WITHOUT ATEZOLIZUMAB IN TRIPLE NEGATIVE, EARLY HIGH-RISK AND LOCALLY ADVANCED BREAST CANCER. NEOTRIP MICHELANGELO RANDOMIZED STUDY
 Ann Oncol. (2022);33(5):534-543

Bianchini GS, De Angelis C, Licata L, Gianni LS
TREATMENT LANDSCAPE OF TRIPLE-NEGATIVE BREAST CANCER - EXPANDED OPTIONS, EVOLVING NEEDS
 Nat Rev Clin Oncol (2022), 19(2):91-113.
 (§ Co-corresponding)

Bianchini GS, Arpino G, Biganzoli L, Lonardi S, Puglisi F, Santini D, Lambertini M, Pappagallo G
EMETOGENICITY OF ANTIBODY-DRUG CONJUGATES (ADCs) IN SOLID TUMORS WITH A FOCUS ON TRASTUZUMAB DERUXTECAN: INSIGHTS FROM AN ITALIAN EXPERT PANEL
 Cancers (2022), 14(4)
 (§ Corresponding)

Ocaña A, Chacón JL, Calvo L, Antón A, Mansutti M, Albanell J, Martínez MT, Lahuerta A, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chan A, Morales S, Herranz J, Tusquets I, Chiesa M, Caballero R, Valagussa P, **Bianchini G**, Alba E, Gianni L
DERIVED NEUTROPHIL-TO-LYMPHOCYTE RATIO PREDICTS PATHOLOGICAL COMPLETE RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER
 Frontiers in Oncology (2022), 11

Morganti S, **Bianchini G**, Giordano A, Giuliano M, Curigliano G, Criscitiello C
HOW I TREAT HER2-POSITIVE EARLY BREAST CANCER: HOW LONG ADJUVANT TRASTUZUMAB IS NEEDED?
 ESMO Open (2022), 7(2):100428.

Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, Molinelli C, Adamo V, **Bianchini G**, Biganzoli L, Curigliano G, De Laurentiis M, Fabi A, Frassoldati A, Gennari A, Marchiò C, Perrone F, Viale G, Zamagni C, Zambelli A, Del Mastro L, De Placido S, Guarneri V, Marchetti P, Puglisi F
DEFINITION OF HIGH-RISK EARLY HORMONE-POSITIVE HER2-NEGATIVE BREAST CANCER: A CONSENSUS REVIEW
 Cancers Basel (2022), 14(8).

Gianni L, Colleoni M, Bisagni G, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, **Bianchini G**, Frassoldati A, Maffei I, Valagussa P, Viale G.
EFFECTS OF NEOADJUVANT TRASTUZUMAB, PERTUZUMAB AND PALBOCICLIB ON KI67 IN HER2 AND ER-POSITIVE BREAST CANCER
 NPJ Breast Cancer (2022), 8(1):1

Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, **Bianchini G**, Andr  F, Curigliano G
IMMUNOTHERAPY FOR EARLY TRIPLE NEGATIVE BREAST CANCER: RESEARCH AGENDA FOR THE NEXT DECADE
 NPJ Breast Cancer (2022), 8(1):23

Cort s J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, Kim MH, Tseng L-M, Petry V, Chung C-F et al (DESTINY-Breast03 Trial Investigators: **Bianchini G**)
TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB EMTANSINE FOR BREAST CANCER
 New England Journal of Medicine (2022), 386(12):1143-1154.

Vigan  L, Locatelli A, Ulisse A, Galbardi B, Dugo M, Tosi D, Tacchetti C, Daniele T, Gy rffy B, Sica L, Macchini M, Zambetti M, Zambelli S, **Bianchini G**, Gianni L
MODULATION OF THE ESTROGEN/ERBB2 RECEPTORS CROSSTALK BY CDK4/6 INHIBITION TRIGGERS SUSTAINED SENESCENCE IN ESTROGEN RECEPTOR AND ERBB2 POSITIVE BREAST CANCER
 Clin Cancer Res. (2022);28(10):2167-2179
 (§ Co-last and Co-corresponding)

Bianchini G, Licata L, Viale G, Gianni L
IMMUNOTHERAPY IN EARLY TNBC: LESSON LEARNED, QUESTION REMAINING
 Annals of Oncology (2022), 33(11):1091-1093
 (§ Corresponding)

Rugo HS, **Bianchini G**, Cortes J, Henning JW, Untch M
OPTIMIZING TREATMENT MANAGEMENT OF TRASTUZUMAB DERUXTECAN IN CLINICAL PRACTICE OF BREAST CANCER
 ESMO Open (2022), 7(4):100553

Agostinetti E, Montemurro F, Puglisi F, Criscitiello C, **Bianchini G**, Del Mastro L, Introna M, Tondini C, Santoro A, Zambelli A
IMMUNOTHERAPY FOR HER2-POSITIVE BREAST CANCER: CLINICAL EVIDENCE AND FUTURE PERSPECTIVES
 Cancers (2022), 14(9)

Paolino G, Pampena R, Di Nicola MR, Longo C, Rognone A, Zambelli S, **Bianchini G**, Mercuri SR
DERMATOLOGICAL AND DERMOSCOPIC BASELINES IN BRCA MUTATION CARRIERS
 Front Med Lausanne (2022), 9:863468

Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, **Bianchini G**, Pruneri G, Vernieri C
PREDICTIVE ROLE OF CD36 EXPRESSION IN HER2-POSITIVE BREAST CANCER PATIENTS RECEIVING NEOADJUVANT TRASTUZUMAB
 JNCI: Journal of the National Cancer Institute (2022), 114(12):1720-1727
 (§Co-last author)

Fabi A, Buono G, Bria E, **Bianchini G**, Curigliano G, De Laurentiis M, De Placido S, Del Mastro L, Guarneri V, Generali D, Livi L, Lorusso V, Montemurro F, Puglisi F, Vigneri P, Zambelli A, Arpino G.
CONTROVERSIAL TOPICS IN METASTATIC HR+/HER2- BREAST CANCER: GUIDING TREATMENT BY A MODIFIED DELPHI APPROACH
 Front Oncol. (2022); 12:950861

Geyer CE, Jr., Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G et al (Appendix: **Bianchini G**)
OVERALL SURVIVAL IN THE OLYMPIA PHASE III TRIAL OF ADJUVANT OLAPARIB IN PATIENTS WITH GERMLINE PATHOGENIC VARIANTS IN BRCA1/2 AND HIGH-RISK, EARLY-BREAST CANCER
 Annals of Oncology (2022), 33(12):1250-1268

Buono G, Arpino G, Del Mastro L, Fabi A, Generali D, Puglisi F, Zambelli A, Cinieri S, Nuzzo F, Di Lauro V, Vigneri P, **Bianchini G**, Montemurro F, Alessandra G, De Laurentiis M
EXTENDED ADJUVANT ENDOCRINE TREATMENT FOR PREMENOPAUSAL WOMEN: A DELPHI APPROACH TO GUIDE CLINICAL PRACTICE
 Frontiers in Oncology (2022), 12

Hurvitz SA, Bachelot T, **Bianchini G**, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P
ASTEFANIA: ADJUVANT ADO-TRASTUZUMAB EMTANSINE AND ATEZOLIZUMAB FOR HIGH-RISK, HER2-POSITIVE BREAST CANCER
 Future Oncol (2022), 18(32):3563-3572

2023 Hurvitz, S. A., R. Hegg, W.-P. Chung, S.-A. Im, W. Jacot, V. Ganju, J. W. Y. Chiu, B. Xu, E. Hamilton, S. Madhusudan, H. Iwata, S. Altintas, J.-W. Henning, G. Curigliano, J. M. Perez-Garcia, S.-B. Kim, V. Petry, C.-S. Huang, W. Li, J.-S. Frenel, S. Antolin, W. Yeo, **G. Bianchini**, S. Loi, J. Tsurutani, A. Egorov, Y. Liu, J. Cathcart, S. Ashfaq and J. Cortés
TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB EMTANSINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER: UPDATED RESULTS FROM DESTINY-BREAST03, A RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL
 The Lancet (2023), 401(10371):105-117

Miglietta F, Fabi A, Generali D, Dieci MV, Arpino G, **Bianchini G**, Cinieri S, Conte PF, Curigliano G, De Laurentis M, Del Mastro L, De Placido S, Gennari A, Puglisi F, Zambelli A, Perrone F, Guarneri V.
OPTIMIZING CHOICES AND SEQUENCES IN THE DIAGNOSTIC-THERAPEUTIC LANDSCAPE OF ADVANCED TRIPLE-NEGATIVE BREAST CANCER: AN ITALIAN CONSENSUS PAPER AND CRITICAL REVIEW
 Cancer Treatment Reviews (2023)

Licata L, Cosentini D, De Sanctis R, Iorfida M, Caremoli ER, Vingiani A, Simoncini EL, Pruner G, Munzone E, **Bianchini G**, Zambelli A, Tondini C.
MULTIGENE SIGNATURES FOR EARLY BREAST CANCER IN CLINICAL PRACTICE: A REPORT OF THE LOMBARDY GENOMIC ASSAYS FOR BREAST CANCER WORKING GROUP
 Frontiers in Oncology (2023), 13

L. Licata*, M. Mariani*, F. Rossari*, G. Viale, G. Notini, M. Naldini, C. Bosi, M. Piras, M. Dugo, **G. Bianchini§**
TUMOR TISSUE- AND LIQUID BIOPSY-BASED BIOMARKERS FOR IMMUNOTHERAPY IN BREAST CANCER
 The Breast (2023), 69:330-341
 (§ Last and corresponding author)

N. Turner, C. Huang-Bartlett, K. Kalinsky, M. Cristofanilli, **G. Bianchini**, S. Chia, H. Iwata, W. Janni, C. X Ma, E. L. Mayer, Y. Hee Park, S. Fox, X. Liu, S. McClain, F. Clement Bidard
DESIGN OF SERENA-6, A PHASE III SWITCH TRIAL WITH CAMIZESTRANT IN ESR1-MUTANT BREAST CANCER DURING FIRST-LINE TREATMENT
 Future Oncology (2023), 19(8), pp. 559–573

Malorni L§, **Bianchini G§**, Caputo R, Zambelli A, Puglisi F, Bianchi GV, Del Mastro L, Paris I, Montemurro F, Allegrini G, Colleoni M, Tamperi S, Zamagni C, Cazzaniga ME, Orditura M, Guarneri V, Castelletti D, Benelli M, Di Marino M, Arpino G, De Laurentiis M.
SERUM THYMIDINE KINASE ACTIVITY IN PATIENTS WITH HR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER TREATED WITH RIBOCICLIB PLUS LETROZOLE: RESULTS FROM THE PROSPECTIVE BIOITALEE TRIAL
 European Journal of Cancer (2023)
 (§ Co-first author)

L. Licata, G. Viale, M. Giuliano, G. Curigliano, M. Chavez-MacGregor, J. Foldi, O. Oke, J. Collins, L. Del Mastro, F. Puglisi, F. Montemurro, C. Vernieri, L. Gerratana, S. Giordano, A. Rognone, L. Sica, O. Gentilini, S. Cascinu, L. Pusztai, A. Giordano, C. Criscitiello, **G. Bianchini§**
ONCOTYPE DX RESULTS INCREASE CONCORDANCE IN ADJUVANT CHEMOTHERAPY RECOMMENDATIONS FOR EARLY-STAGE BREAST CANCER
 NPJ Breast Cancer (2023), 9(1), 51
 (§ Last and corresponding author)

- C. Corti, C. De Angelis, **G. Bianchini**, L. Malorni, M. Giuliano, E. Hamilton, R. Jeselsohn, K. Jhaveri, G. Curigliano, C. Criscitiello
NOVEL ENDOCRINE THERAPIES: WHAT IS NEXT IN ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER?
 Cancer Treat Rev (2023):117
- C. Criscitiello, C. Corti, M. De Laurentiis, **G. Bianchini**, B. Pistilli, S. Cinieri, L. Castellan, G. Arpino, P. Conte, F. Di Meco, A. Gennari, V. Guarneri, L. Visani, L. Livi, P. Marchetti, F. Puglisi, G. Viale, L. Del Mastro, S. De Placido, G. Curigliano
TUCATINIB'S JOURNEY FROM CLINICAL DEVELOPMENT TO CLINICAL PRACTICE: NEW HORIZONS FOR HER2-POSITIVE METASTATIC DISEASE AND PROMISING PROSPECTS FOR BRAIN METASTATIC SPREAD
 Cancer Treat Rev (2023):120
- L. Licata, M. Barreca, B. Galbardi, M. Dugo, G. Viale, B. Györfy, T. Karn, L. Pusztai, L. Gianni, M. Callari and **G. Bianchini**§
BREAST CANCERS WITH HIGH PROLIFERATION AND LOW ER-RELATED SIGNALING HAVE POOR PROGNOSIS AND UNIQUE MOLECULAR FEATURES WITH IMPLICATIONS FOR THERAPY
 British Journal of Cancer (2023); 129, pages 2025–2033
 (§ Last and corresponding author)
- F. André, Y. Hee Park, S.B. Kim, T. Takano, S.A. Im, G. Borges, J.P. Lima, S. Aksoy, J.G. Gregori, M. De Laurentiis, **G. Bianchini**, R. Roylance, Y. Miyoshi, A. Armstrong, R. Sinha, M. Ruiz Borrego, E. Lim, J. Ettl, R. Yerushalmi, F. Zagouri, F.P. Duhoux, T. Fehm, D. Gambhire, J. Cathcart, C. Wu, C. Chu, A. Egorov, I. Krop.
TRASTUZUMAB DERUXTECAN VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER (DESTINY-BREAST02): A RANDOMISED, OPEN-LABEL, MULTICENTRE, PHASE 3 TRIAL
 Lancet. (2023);401(10390):1773-1785
- X. Qian Wang, E. Danenberg, C.S. Huang, D. Egle, M. Callari, B. Bermejo, M. Dugo, C. Zamagni, M. Thill, A. Anton, S. Zambelli, S. Russo, E.M. Ciruelos, R. Greil, B. Györfy, V. Semiglazov, M. Colleoni, C. Kelly, G. Mariani, L. Del Mastro, O. Biasi, R. S. Seitz, P. Valagussa, G. Viale, L. Gianni, **G. Bianchini***, H. Raza Ali*
HIGHLY MULTIPLEXED IMAGING PREDICTS IMMUNOTHERAPY RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
 Nature (2023) 621, pages 868–876
 (*co-last, co-corresponding author)
- C. Bosi, Á. Bartha, B. Galbardi, G. Notini, M.M. Naldini, L. Licata, G. Viale, M. Mariani, B. Pistilli, H Raza Ali, F. Andre, M. Piras, M. Callari, M. Barreca, A. Locatelli, L. Viganò, C. Criscitiello, L. Pusztai, G. Curigliano, B. Györfy, M. Dugo, **G. Bianchini***
PAN-CANCER ANALYSIS OF ANTIBODY-DRUG CONJUGATE TARGETS AND PUTATIVE PREDICTORS OF TREATMENT RESPONSE
 European Journal Cancer (2023) Vol. 195 Pages 113379
 (*Last and corresponding author)
- 2024** Dri, A., G. Arpino, **G. Bianchini**, G. Curigliano, R. Danesi, M. De Laurentiis, L. Del Mastro, A. Fabi, D. Generali, A. Gennari, V. Guarneri, D. Santini, E. Simoncini, C. Zamagni and F. Puglisi
BREAKING BARRIERS IN TRIPLE NEGATIVE BREAST CANCER (TNBC); UNLEASHING THE POWER OF ANTIBODY-DRUG CONJUGATES (ADCS)
 Cancer Treat Rev. (2024); 123:102672
- L.Licata, R. De Sanctis, A. Vingiani, D. Cosentini, M. Iorfida, E. Rota Caremoli, I.Sassi, B. Fernandes, A. Gianatti, E. Guerini-Rocco, C. Zambelli, E. Munzone, E. L. Simoncini, C. Tondini, O. Gentilini, A. Zambelli, G. Prunerì, **G. Bianchini**
REAL-WORLD USE OF MULTIGENE SIGNATURES IN EARLY BREAST CANCER: DIFFERENCES TO CLINICAL TRIALS
 Breast Cancer Research and Treatment (2024);205(1):39-48

Morganti, S., A. Marra, C. De Angelis, A. Toss, L. Licata, F. Giugliano, B. Taurelli Salimbeni, P. P. M. Berton Giachetti, A. Esposito, A. Giordano, **G. Bianchini**, J. E. Garber, G. Curigliano, F. Lynce and C. Criscitiello

PARP INHIBITORS FOR BREAST CANCER TREATMENT: A REVIEW

JAMA Oncol (2024) 10(5):658-670

Notini, G., M. M. Naldini, L. Sica, G. Viale, A. Rognone, S. Zambelli, P. Zuccinelli, M. Piras, C. Bosi, M. Mariani, D. Aldrighetti, **G. Bianchini** and L. Licata

MANAGEMENT OF TRASTUZUMAB DERUXTECAN-RELATED NAUSEA AND VOMITING IN REAL-WORLD PRACTICE

Front Oncol (2024); 14:1374547

Ungvari, Z., A. Ungvari, **G. Bianchini** and B. Györfy

PROGNOSTIC SIGNIFICANCE OF A SIGNATURE BASED ON SENESENCE-RELATED GENES IN COLORECTAL CANCER

Geroscience (2024) 46(5): 4495-4504

Licata, L., M. V. Dieci, C. De Angelis, C. Marchiò, F. Miglietta, L. Cortesi, A. Fabi, P. Schmid, J. Cortes, L. Pusztai, **G. Bianchini*** and G. Curigliano

NAVIGATING PRACTICAL CHALLENGES IN IMMUNOTHERAPY FOR METASTATIC TRIPLE NEGATIVE BREAST CANCER

Cancer Treatment Reviews (2024)128: 102762

(*co-last, co-corresponding author)

Cortés, J., S. A. Hurvitz, S.-A. Im, H. Iwata, G. Curigliano, S.-B. Kim, J. W. Y. Chiu, J. L. Pedrini, W. Li, K. Yonemori, **G. Bianchini**, S. Loi, G. S. Borges, X. Wang, T. Bachelot, S. Nakatani, S. Ashfaq, Z. Liang, A. Egorov and E. Hamilton

TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER: LONG-TERM SURVIVAL ANALYSIS OF THE DESTINY-BREAST03 TRIAL

Nature Medicine (2024) 30(8):2208-2215

Mariani, M., G. Viale, B. Galbardi, L. Licata, C. Bosi, M. Dugo, G. Notini, M. M. Naldini, M. Callari, C. Criscitiello, L. Pusztai and **G. Bianchini**

COMPLETION RATE AND POSITIVE RESULTS REPORTING AMONG IMMUNOTHERAPY TRIALS IN BREAST CANCER, 2004-2023

JAMA Netw Open (2024) 7(7): e2423390

Zambelli, A., L. Cortesi, M. Gaudio, G. Arpino, **G. Bianchini**, F. Caruso, S. Cinieri, G. Curigliano, L. Del Mastro, S. De Placido, A. Fabi, L. Fortunato, D. Generali, A. Gennari, S. Gori, G. Grandi, V. Guarneri, M. Klinger, L. Livi, C. Marchiò, I. Palumbo, P. Panizza, G. Pravettoni, G. Pruneri, F. Puglisi, A. Sapino, C. Tinterri, D. Turchetti and M. De Laurentiis

PARP-INHIBITORS IN THE THERAPEUTIC LANDSCAPE OF BREAST CANCER PATIENTS WITH BRCA1 AND BRCA2 PATHOGENIC GERMLINE VARIANTS: AN ITALIAN CONSENSUS PAPER AND CRITICAL REVIEW

Cancer Treat Rev (2024)130: 102815

Harbeck, N., E. Ciruelos, G. Jerusalem, V. Müller, N. Niikura, G. Viale, R. Bartsch, C. Kurzeder, M. J. Higgins, R. M. Connolly, S. Baron-Hay, M. Gíon, V. Guarneri, **G. Bianchini**, H. Wildiers, S. Escrivá-de-Romaní, M. Prahlan, H. Bridge, N. Kuptsova-Clarkson, N. Scotto, S. Verma, N. U. Lin and DESTINY-Breast 12 study group

TRASTUZUMAB DERUXTECAN IN HER2-POSITIVE ADVANCED BREAST CANCER WITH OR WITHOUT BRAIN METASTASES: A PHASE 3B/4 TRIAL

Nature Medicine (2024) 30(8):2208-2215

Dugo, M., C. S. Huang, D. Egle, B. Bermejo, C. Zamagni, R. S. Seitz, T. J. Nielsen, M. Thill, A. Antón-Torres, S. Russo, E. M. Ciruelos, B. L. Schweitzer, D. T. Ross, B. Galbardi, R. Greil, V. Semiglazov, B. Györffy, M. Colleoni, C. M. Kelly, G. Mariani, L. Del Mastro, O. Blasi, M. Callari, L. Pusztai, P. Valagussa, G. Viale, L. Gianni and **G. Bianchini***

THE IMMUNE-RELATED 27-GENE SIGNATURE DETERMINES RESPONSE TO NEOADJUVANT ATEZOLIZUMAB PLUS CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER

Clin Cancer Res (2024) 30(21): 4900-4909

(*corresponding author)

Mule N, Maffei G, Cubeddu R, Santangelo C, **Bianchini G**, Panizza P, Taroni P.

MONITORING OF NEOADJUVANT CHEMOTHERAPY THROUGH TIME DOMAIN DIFFUSE OPTICS: BREAST TISSUE COMPOSITION CHANGES AND COLLAGEN DISCRIMINATIVE POTENTIAL

Biomed Opt Express. (2024);15(8):4842-4858

Barreca, M., M. Dugo, B. Galbardi, B. Györffy, Valagussa, D. Besozzi, G. Viale, **G. Bianchini***, L. Gianni, M. Callari, N.-P. consortium and T. c. Neo

DEVELOPMENT AND VALIDATION OF A GENE EXPRESSION-BASED BREAST CANCER PURITY SCORE

NPJ Precision Oncology 8(1): 242

(*Co-last author)

Dent, R., F. André, A. Gonçalves, M. Martin, P. Schmid, F. Schütz, S. Kümmel, S. M. Swain, A. Bilici, D. Loirat, R. Villalobos Valencia, S. A. Im, Y. H. Park, M. De Laurentis, M. Colleoni, V. Guarneri, **G. Bianchini**, H. Li, Z. Kirchmayer Machackova, J. Mouta, R. Deurloo, X. Gan, M. Fan, A. Mani, A. Swat and J. Cortés

IMPASSION132 DOUBLE-BLIND RANDOMISED PHASE III TRIAL OF CHEMOTHERAPY WITH OR WITHOUT ATEZOLIZUMAB FOR EARLY RELAPSING UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER

Annals of Oncology (2024) 35(7): 630-642

2025

Corti C, Binboğa Kurt B, Koca B, Rahman T, Conforti F, Pala L, **Bianchini G**, Criscitiello C, Curigliano G, Garrido-Castro AC, Kabraji SK, Waks AG, Mittendorf EA, Tolaney SM.

ESTROGEN SIGNALING IN EARLY-STAGE BREAST CANCER: IMPACT ON NEOADJUVANT CHEMOTHERAPY AND IMMUNOTHERAPY

Cancer Treat Rev. (2025) 132:102852

Kalinsky, K., G. Bianchini, E. Hamilton, S. L. Graff, K. H. Park, R. Jeselsohn, M. Martin, R. M. Layman, S. A. Hurvitz, S. Sammons, P. A. Kaufman, M. Muñoz, J. I. Lai, H. Knoderer, C. Sandoval, A. R. Chawla, B. Nguyen, Y. Zhou, E. Ravenberg, L. M. Litchfield, L. Smyth and S. A. Wander

ABEMACICLIB PLUS FULVESTRANT IN ADVANCED BREAST CANCER FOLLOWING PROGRESSION ON CDK4/6 INHIBITION: RESULTS FROM THE PHASE III POSTMONARCH TRIAL

J Clin Oncol (2025): Jco2402086

Ungvari, Z., Á. Bartha, A. Ungvari, M. Fekete, **G. Bianchini** and B. Györffy

PROGNOSTIC IMPACT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP1R) EXPRESSION ON CANCER SURVIVAL AND ITS IMPLICATIONS FOR GLP-1R AGONIST THERAPY: AN INTEGRATIVE ANALYSIS ACROSS MULTIPLE TUMOR TYPES

Geroscience (2025) 47 (3): 4413-4427

McArthur HL, Tolaney SM, Dent R, Schmid P, Asselah J, Liu Q, Meisel JL, Niihara N, Park YH, Werutsky G, **Bianchini G**, Andersen JC, Kozarski R, Rokutanda N, Pistilli B, Loibl S.

TROPION-BREAST04: A RANDOMIZED PHASE III STUDY OF NEOADJUVANT DATOPOTAMAB DERUXTECAN (DATO-DXD) PLUS DURVALUMAB FOLLOWED BY ADJUVANT DURVALUMAB VERSUS STANDARD OF CARE IN PATIENTS WITH TREATMENT-NAÏVE EARLY-STAGE TRIPLE NEGATIVE OR HR-LOW/HER2- BREAST CANCER

Therapeutic Advances in Medical Oncology (2025) 17: 17588359251316176

Bianchini G, Viale G, Dugo M.

FROM INTRINSIC TO ADAPTIVE CLUSTERS IN BREAST CANCER

Cancer Cell. (2025) 43(2):171-173

Berton Giachetti, P. P. M., S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M. G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, **G. Bianchini**, G. Curigliano, C. De Angelis and C. Criscitiello

SURVIVAL FOLLOWING CDK4/6 INHIBITOR THERAPY FOR HORMONE RECEPTOR-POSITIVE, ERBB2-NEGATIVE METASTATIC BREAST CANCER

JAMA Netw Open (2025) 8(2): e2461067

Callari M, Dugo M, Barreca M, Györfy B, Galbardi B, Vigano L, Locatelli A, Dall'Ara C, Ferrarini M, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Frassoldati A, Biasi O, Pusztai L, Valagussa P, Viale G, Gianni L, **Bianchini G**.

DETERMINANTS OF RESPONSE AND MOLECULAR DYNAMICS IN HER2+ER+ BREAST CANCERS FROM THE NA-PHER2 TRIAL RECEIVING HER2-TARGETED AND ENDOCRINE THERAPIES

Nat Commun. (2025) 16(1): 2195

Park YH, **Bianchini G**, Cortés J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scotté F, Schwartzberg L, Navari RM, Aapro M, Rugo HS.

NAUSEA AND VOMITING IN AN EVOLVING ANTICANCER TREATMENT LANDSCAPE: LOND-DELAYED AND EMETOGENIC ANTIBODY-DRUG CONJUGATES

Future Oncol. (2025) 21 (10):1261-1272

Meric-Bernstam, F., A. Bardia, P. Bossi, **G. Bianchini**, F. Gatlin, R. V. Lalla, B. Melosky, N. Niikura, T. A. Yap, S. S. Kim, R. Rajagopalan, R. M. Fairhurst, S. L. Graff and H. S. Rugo

PROPHYLAXIS, CLINICAL MANAGEMENT, AND MONITORING OF DATOPOTAMAB DERUXTECAN-ASSOCIATED ORAL MUCOSITIS/STOMATITIS

The Oncologist (2025) 30(3)

Turner, N., C. Saura, P. Aftimos, E. van den Tweel, M. Oesterholt, N. Koper, M. Colleoni, E. Kaczmarek, K. Punie, X. Song, A. Armstrong, G. Bianchi, A. Stradella, S. Ladoire, J. S. J. Lim, N. Quenel-Tueux, T. J. Tan, S. Escrivá-de-Romaní and J. O'Shaughnessy (TULIP investigators: **Bianchini G**)

TRASTUZUMAB DUOCARMAZINE IN PRETREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE ADVANCED OR METASTATIC BREAST CANCER: AN OPEN-LABEL, RANDOMIZED, PHASE III TRIAL (TULIP)

J Clin Oncol (2025) 43(5): 513-523

Ungvari Z, Fekete M, Varga P, Lehoczki A, Munkácsy G, Fekete JT, **Bianchini G**, Ocana A, Buda A, Ungvari A, Györfy B.

ASSOCIATION BETWEEN RED AND PROCESSED MEAT CONSUMPTION AND COLORECTAL CANCER RISK: A COMPREHENSIVE META-ANALYSIS OF PROSPECTIVE STUDIES

Geroscience. (2025) 47(3): 5123-5140

Bartha Á, Weltz B, Betancourt LH, Gil J, Pinto de Almeida N, **Bianchini G**, Szeitz B, Szadai L, Pla I, Kemény LV, Jánosi ÁJ, Hong R, Rajeh A, Nogueira F, Doma V, Woldmar N, Guedes J, Újfaludi Z, Kim Y, Szarvas T, Pahi Z, Pankotai T, Szasz AM, Sanchez A, Baldetorp B, Tímár J, Németh IB, Kárpáti S, Appelqvist R, Domont GB, Pawlowski K, Wieslander E, Malm J, Fenyo D, Horvatovich P, Marko-Varga G, Györfy B.

MELANOMA PROTEOMICS UNVEILED: HARMONIZING DIVERSE DATA SETS FOR BIOMARKER DISCOVERY AND CLINICAL INSIGHT VIA MEL-PLOT

J Proteome Res. (2025) 24(6): 3117-3128

Kovács SA, Kovács T, Lánckzy A, Paál Á, Hegedűs ZI, Sayour NV, Szabó L, Kovács A, **Bianchini G**, Ferdinandy P, Ocana A, Varga ZV, Fekete JT, Györfy B.

UNLOCKING THE POWER OF IMMUNE CHECKPOINT INHIBITORS: TARGETING YAP1 REDUCES ANTI-PD1 RESISTANCE IN SKIN CUTANEOUS MELANOMA

Br J Pharmacol. (2025) 182(16): 3903-3922

Valsecchi AA, Pisegna S, Antonuzzo A, Arpino G, **Bianchini G**, Biganzoli L, Colloca GF, Criscitiello C, Danesi R, Fabi A, Giusti R, Pau L, Di Maio M, Santini D.

DELPHI CONSENSUS ON THE MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER TREATED WITH SACITUZUMAB GOVITECAN

Oncologist. (2025) 30(5): oyaf088

Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Rizzo V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, **Bianchini G**, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F.

COMPARATIVE ANALYSIS OF DENOSUMAB AND ZOLEDRONIC ACID IN ADVANCED BREAST CANCER PATIENTS RECEIVING CDK4/6 INHIBITORS

The Breast. (2025); 82:104502

Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, **Bianchini G**, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC; SERENA-6 Study Group.

FIRST-LINE CAMEZISTRANT FOR EMERGING ESR1 MUTATED ADVANCED BREAST CANCER

The New Engl Journ. of Med. (2025) ;393(6):569-580

Miglietta F, Razeti MG, Caltavuturo A, Dri A, Valenza C, **Bianchini G**, Biganzoli L, Botticelli A, Caruso M, Cinieri S, Criscitiello C, De Angelis C, De Laurentis M, Del Mastro L, De Placido S, Del Re M, Dieci MV, Fabi A, Generali D, Gennari A, Gerratana L, Giuliano M, Lambertini M, Malapelle U, Malorni L, Meattini I, Paris I, Pruner G, Zamagni C, Zambelli A, Bidard FC, Guarneri V, Puglisi F, Curigliano G, Arpino G.

THE EVOLVING LANDSCAPE OF HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER (EVOLVE): AN ITALIAN DELPHI CONSENSUS REPORT

Crit Rev Oncol Hematol. (2025); 213:104793

Ungvari Z, Fekete M, Buda A, Lehoczki A, Munkácsy G, Scaffidi P, Bonaldi T, Fekete JT, **Bianchini G**, Varga P, Ungvari A, Györfy B.

QUANTIFYING THE IMPACT OF TREATMENT DELAYS ON BREAST CANCER SURVIVAL OUTCOMES: A COMPREHENSIVE META-ANALYSIS.

Geroscience. 2025 Jun 10 doi: 10.1007/s11357-025-01719-1

Giugliano F, De Angelis C, Pistilli B, Viale G, **Bianchini G**, Giuliano M, Malorni L, Taurelli Salimbeni B, Esposito A, Giordano A, Yap TA, Curigliano G, Criscitiello C.

OVERCOMING RESISTANCE TO CDK4/6 INHIBITORS IN HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER: INNOVATIVE COMBINATIONS AND EMERGING STRATEGIES

Cancer Treat Rev. (2025);139: 102980 (2025)

Ungvari Z, Menyhart O, Lehoczki A, Fekete M, **Bianchini G**, Györfy B.

PCSK9 EXPRESSION AND CANCER SURVIVAL: A PROGNOSTIC BIOMARKER AT THE INTERSECTION OF ONCOLOGY AND GEROSCIENCE

Geroscience. 2025 Jun 27. doi:10.1007/s11357-025-01733-3

Blondeaux E, Delucchi V, Mariamidze E, Bernstein-Molho R, Frank S, Ferrari A, Linn S, Kim HJ, Agostinetto E, Paluch-Shimon S, Cortesi L, Di Meglio A, Balmana J, Yerushalmi R, Rodriguez-Wallberg KA, Renaud T, Cui W, Moore HCF, Wong SM, Pogoda K, Lustberg M, Phillips KA, Han S, Puglisi F, Vernieri C, Bajpai J, Sonnenblick A, Rousset-Jablonski C, De Marchis L, De Giorgi U, **Bianchini G**, Teixeira L, Duhoux FP, Villarreal-Garza C, Sini V, Fruscio R, Del Mastro L, Demeestere I, Azim HA Jr, Peccatori FA, Partridge AH, Lambertini M.

BREASTFEEDING AFTER BREAST CANCER IN YOUNG BRCA CARRIERS

J Natl Cancer Inst. (2025) 117(11):2229-2239

Licata L, Mariani M, Viale G, Dent R, Tolaney SM, Schmid P, Hamilton E, Sotiriou C, Pusztai L, **Bianchini G**

TIMING OF RECURRENCE AFTER NEOADJUVANT CHEMO-IMMUNOTHERAPY IN PATIENTS WITH EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER

Clin Cancer Res. (2025); 31(18):3916-3921

Bianchini G, Fabi A, Guarneri V, Arpino G, De Laurentis M, Zambelli A, Zamagni C, Biganzoli L, Puglisi F, Santini D.

MANAGEMENT OF TRASTUZUMAB DERUXTECAN-RELATED ADVERSE EVENTS IN BREAST CANCER: ITALIAN EXPERT PANEL RECOMMENDATIONS

Future Oncol. (2025); 21(20):2565-2573

Balko JM, Licata L, Wang XQ, Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Russo S, Sevillano E, Ciruelos EM, Greil R, Semiglazov V, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Zambelli S, Viale G, Callari M, Viale G, Pusztai L, Gianni L, Ali HR, **Bianchini G**.

TUMOR-SPECIFIC MAJOR HISTOCOMPATIBILITY-II EXPRESSION PREDICTS PATHOLOGICAL COMPLETE RESPONSE TO ATEZOLIZUMAB COMBINED CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER

NPJ Breast Cancer (2025);11(1):103

Saura C, Wildiers H, **Bianchini G**, García-Saenz JÁ, Allignol A, Logue A, Lucerna M, Stamenitis S, De Laurentiis M.

EUROPEAN EXPERIENCE OF PATIENTS WITH HER2-POSITIVE ADVANCED/METASTATIC BREAST CANCER ACCESSING TRASTUZUMAB DERUXTECAN THROUGH A NAMED PATIENT PROGRAM: THE EUROPA T-DXD STUDY

Front Oncol. (2025); 15:1650981

Foldi J, Xiong K, Liu M, Robbins CJ, Chen F, Zhan H, Burela S, Dai J, Karn PL, Dugo M, **Bianchini G**, Lee AV, Oesterreich S, Rimm DL, Pusztai L.

MIXED MOLECULAR SUBTYPES COEXIST IN ESTROGEN RECEPTOR HETEROGENEOUS PRIMARY BREAST CANCERS

JCO Precis Oncol. (2025) ;9: e2500529

Nieto-Jiménez C, Paniagua-Herranz L, Bosi C, Poyatos-Racionero E, Pedregal M, Moreno V, Calvo E, Domínguez-Jurado E, Hernández T, Pérez-Segura P, Györfy B, Alonso-Moreno C, **Bianchini G**, Ocana A.

UNDERSTANDING THE CHEMICAL CHARACTERISTICS OF PAYLOADS AND THE EXPRESSION OF TUMOR-ASSOCIATED ANTIGENS OF ADCs IN CLINICAL DEVELOPMENT

ACS Omega (2025);10(46):55126-55136

Park YH, Cortes J, Modi S, Hurvitz SA, **Bianchini G**, Iwata H, Shitara K, Siena S, Goto Y, Ku GY, Powell CA, Swain SM, Arunachalam M, Janek M, Cheng Y, Chu C, Verma P, Kuptsova-Clarkson N, Mathias E, Goodman E, Rugo HS.

CHARACTERIZATION OF THE SAFETY PROFILE OF TRASTUZUMAB DERUXTECAN BY DOSE: A POOLED ANALYSIS ACROSS DESTINY STUDIES

Oncologist (2025); 31(1) oyaf396

2026

Persano I, Licata L, Piras M, Ata-Shiroshita A, Naldini MM, Bosi C, Notini G, Mariani M, Chiavassa A, Patané F, Zanibelli C, Rognone A, Sica L, Zambelli S, Zucchinelli P, Guarino A, Pasetti M, Di Micco R, Gentilini OD, **Bianchini G (*)**, Viale G.

DE-ESCALATION STRATEGIES FOR AXILLARY MANAGEMENT AT PRIMARY SURGERY IN EARLY BREAST CANCER: INSIGHTS AND IMPLICATIONS FOR MEDICAL ONCOLOGY PRACTICE

Cancer Treat Rev. (2026);143: 103092

(* co-corresponding author)

Bianchini G (*), Malorni L, Caputo R, Zambelli A, Puglisi F, Bianchi GV, Del Mastro L, Paris I, Montemurro F, Colleoni M, Allegrini G, Tamperi S, Zamagni C, Cazzaniga ME, Orditura M, Guarneri V, Adamo V, Romagnoli E, Valerio MR, Cinieri S, Benelli M, Callari M, Valsecchi D, Castelletti D, Grasso D, Fenderico N, Arpino G, De Laurentiis M.

ROLE OF ctDNA IN PREDICTING THE OUTCOME OF PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER TREATED WITH FIRST-LINE RIBOCICLIB AND LETROZOLE: BIOLTALEE TRIAL

Clin Cancer Res. (2026); 32(12):2428-2437

(* co-first author)

Notini G, **Bianchini G**, Pérez-García JM, Cortés J.

BEYOND THE HYPE: ANTIBODY-DRUG CONJUGATES ARE ADVANCING FASTER THAN OUR CLINICAL STRATEGY

PLoS Med. (2026); 23(1):e1004930

Mazzoli G, Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Fotia G, De Monte M, Ligorio F, Jacobs F, Armani G, Zurlo C, Menichetti A, Griguolo G, Faso V, Schianca AC, Munzone E, Marra A, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarnieri V, Prunerì G, Mariani L; **PALMARES-2 study group**; Vernieri C.

EFFECTIVENESS COMPARISON OF FIRST-LINE CDK4/6 INHIBITORS IN PATIENTS WITH HORMONE-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER ACCORDING TO TUMOR HISTOLOGY: A SUB-ANALYSIS OF THE REAL-WORLD, MULTICENTER, ITALIAN STUDY PALMARES-2.

Breast. (2026); 86:104692

Ungvari Z, Menyhart O, Ocana A, Lehocski A, Fekete M, **Bianchini G (*)**, Györfy B.

SUBTYPE-SPECIFIC SIRTUIN EXPRESSION SIGNATURES LINK MITOCHONDRIAL-EPIGENETIC NETWORKS TO BREAST CANCER SURVIVAL

Geroscience. 2026 Feb 16 doi: 10.1007/s11357-026-02143-9

(* co-last author)

Buonaiuto R, Caltavuturo A, Di Rienzo R, Grieco A, Mangiacotti FP, Longobardi A, Cantile V, Molinaro V, Pagliuca M, Buono G, De Placido P, Pietrolungo E, Forestieri V, Martinelli C, di Lauro V, Leo L, D'Aiuto M, **Bianchini G**, Criscitiello C, Bianco R, Del Mastro L, De Laurentiis M, Arpino G, De Angelis C, Giuliano M.

ANALYSIS OF A LARGE LANGUAGE MODEL DECISION MAKING IN HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE EARLY BREAST CANCER

JCO Clin Cancer Inform. 2026 Mar 10 doi:10.1200/CCI-25-00230

Scafetta R, Troiano R, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Donato M, Foderaro S, Venuti F, Vilardi FA, Rizzo V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Garrone O, Domati F, Piombino C, Lisa FSD, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Livi L, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, **Bianchini G**, Fabbri MA, Giorgi U, Vici P, Toss A, Ruatta F, Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Chirco A, D'Alessandro S, Vincenzi B, Tonini G, Santini D, Pantano F.

DENOSUMAB IS ASSOCIATED WITH LONGER REAL-WORLD PROGRESSION-FREE SURVIVAL IN BRCA1/2-MUTATED HR+ /HER2- BREAST CANCER PATIENTS WITH BONE METASTASES RECEIVING CDK4/6 INHIBITORS: A MULTICENTER ITALIAN STUDY

European Journal of Cancer. (2026) 239:116703

Dent R, Shao Z, Schmid P, Cortes J, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Ramírez EM, Basaran G, Stradella A, Mathiba R, Chen SC, Shen K, Wéber Á, Battelli N, Niikura N, Luo T, Chae YS, Fischbach N, Garbaos G, Patera A, Zhao K, Vuković P, Maxwell MJ, Traina T; **TROPION-Breast02 investigators**

DATOPOTAMAB DERUXTECAN IN PATIENTS WITH UNTREATED, ADVANCED TRIPLE-NEGATIVE BREAST CANCER (TROPION-BREAST02): A RANDOMISED, OPEN-LABEL, INTERNATIONAL, PHASE III TRIAL

Annals of Oncology (2026): S0923-7534(26)00130-4 doi: 10.1016/j.annonc.2026.03.008

Vezzoli E, Pinos R, Galbiati S, Zambroni D, Dall'Ara C, Locatelli A, Colombo E, Galbardi B, Viganò L, Lavagnino Z, Scielzo C, De Palma C, **Bianchini G**, Tacchetti C, Daniele T.

DERUXTECAN-BASED ANTIBODY-DRUG-CONJUGATES INDUCE SENESENCE IN HER2-POSITIVE BREAST CANCER

Sci Rep. (2026);16(1):16106. doi: 10.1038/s41598-026-47488-5

Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Venuti F, Vilardi FA, Rizzo V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, La Cesa A, Botticelli A, Scagnoli S, Pisegna S, Criscitiello C, Chirco A, D'Alessandro S, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Grasso A, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Bonomo MV, Portarena I, Irelli A, Cretella E, Porta C, **Bianchini G**, Fabbri MA, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Altomare V, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F.

COMPARATIVE REAL-WORLD PROGRESSION FREE SURVIVAL OF CDK4/6 INHIBITORS IN HR+/HER2- BREAST CANCER PATIENTS WITH BONE METASTASES

Oncologist (2026) 31(5):oyag146

De Angelis C, de Biase D, Gerratana L, Arpino G, **Bianchini G**, Castellano I, Curigliano G, Del Mastro L, Fabi A, Fusco N, Gennari A, Guarneri V, Zamagni C, Zambelli A, Malapelle U, Puglisi F.

INTEGRATING PIK3CA TESTING INTO CLINICAL PRACTICE FOR ADVANCED HR+/HER2- BREAST CANCER: AN EXPERT CONSENSUS

Breast. (2026); 87:104786

Bidard FC, Barrios C, **Bianchini G**, Brufsky AM, Chia S, Cortes J, Cristofanilli M, Curigliano G, Dawood S, Fasching PA, Gerratana L, Giordano A, Ignatiadis M, Iwata H, Janni W, Lim E, Kalinsky K, Ma CX, Mayer EL, Medford AJ, Mouabbi JA, O'Shaughnessy J, Park YH, Pascual J, Razavi P, Sammons S, Sandoval JL, Sisca L, Tarantino P, Wander SA, Werutsky G, Turner NA.

SERENA-6 INTERPRETATION AND CLINICAL IMPLICATIONS: INTERCEPTING ENDOCRINE RESISTANCE IN METASTATIC BREAST CANCER

NPJ Breast Cancer (2026); 12(1):80

Uggè M, Fracassi C, Tascini AS, Giansanti V, Genova F, Dugo M, Giannese F, Basso V, Ghirardi C, Smart CE, Doglioni C, Casorati G, Dellabona P, Zambelli S, Servitja Tormo S, Cruz Jurado J, Gianni L, Bonaldi T, Agresti A, Mondino A, **Bianchini G***, Bernardi R.

THE PROMYELOCYTIC LEUKEMIA PML PROTEIN COORDINATES IMMUNE EVASION IN TRIPLE-NEGATIVE BREAST CANCER VIA INDEPENDENT AND CONVERGING MECHANISMS

Cell Death Differ. (2026) doi: 10.1038/s41418-026-01781-y
(*co-last author)

Notini G, Galbardi B, Viale G, Naldini MM, Bosi C, De Micheli G, Licata L, Mariani M, Piras M, Criscitiello C, Barreca M, Callari M, Zanibelli C, Patanè F, Chiavassa A, Pérez-García JM, Ali HR, Cortés J, Pusztai L, Gianni L, **Bianchini G (*)**, Dugo M.

PAN-CANCER MULTI-OMIC INTEGRATION OF TROP 2 REVEALS BIOLOGICAL DETERMINANTS AND TRANSLATIONAL IMPLICATIONS FOR ADC THERAPY

NPJ Precis Oncol. 2026 Jun 15;10(1):218. doi: 10.1038/s41698-026-01523-w
(*corresponding author)

Massa D, Foukakis T, Giacchetti S, Desmedt C, Frenel JS, Gasparini E, Kok M, Vigneri P, Jacot W, Vernieri C, Lambertini M, Patanè F, Piacentini F, Bria E, Zambelli A, Trapani D, Botticelli A, Garrone O, Lando S, Matikas A, Someil L, Floris G, Campone M, Ragazzi M, Lips E, Martorana F, Bonomi G, Papakonstantinou A, Nicolè L, Zerdas I, Neven P, Rotolo M, Horlings H, Nucera S, Gudín-De-Vallerin A, Vingiani A, Dei Tos AP, Guarneri V, Dieci MV; **GAMBIT Consortium**

RISK STRATIFICATION AND RELAPSE PATTERN IN TRIPLE-NEGATIVE BREAST CANCER WITH PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT TREATMENT: THE EUROPEAN GAMBIT REAL-WORLD STUDY

Nat Commun. (2026); 10.1038/s41467-026-74056-2. Epub ahead of print

Di Micco R, Saracoglu S, Pfob A, Canevari C, Gallivanone F, Antunovic L, Gelardi F, Scifo P, Neri I, Losio C, Venturini E, Della Vecchia G, Ferrarese G, Rotmensz N, Zuber V, Baleri S, Cisternino G, Corona SP, Calabretto F, Rampa M, Licata L, Viale G, Zambelli S, Sassi I, **Bianchini G**, Panizza P, Chiti A, Heil J, Gentilini OD.

DIAGNOSTIC ACCURACY OF MODERN IMAGING FOLLOWING NEOADJUVANT THERAPY FOR BREAST CANCER: A COMPARATIVE ANALYSIS OF ULTRASOUND VERSUS [18F] FDG PET/MRI IN BREAST RESPONSE ASSESSMENT

Front Oncol. 2026 Jun 18;16:1845216. doi:10.3389/fonc.2026

Oral presentations

First author: 5
Second author: 3
Last author: 1
Middle: 3

- Bianchini G**, Pusztai L, Iwamoto T, Kelly CM, Zambetti M, Fasolo A, Del Conte G, Santarpia L, Symmans WF, Gianni L.
MOLECULAR TUMOR CHARACTERISTICS INFLUENCE ADJUVANT ENDOCRINE TREATMENT OUTCOME
[S1-7] *34th Annual San Antonio Breast Cancer Symposium, 2011*
- Gianni L, **Bianchini G**, Kiermaier A, Bianchi G, Im Y-H, Pienkowski T, Roman L, Liu M-C, Tseng L-M, Ratnayake J, Szado T, Ross GA, Valagussa P
NEOADJUVANT PERTUZUMAB (P) AND TRASTUZUMAB (H): BIOMARKER ANALYSES OF A 4-ARM RANDOMIZED PHASE II STUDY (NEOSPHERE) IN PATIENTS (PTS) WITH HER2-POSITIVE BREAST CANCER (BC)
[S5-1] *34th Annual San Antonio Breast Cancer Symposium, 2011*
- Iwamoto T, Pusztai L, Matsuoka J, Callari M, Kelly CM, Qi Y, Motoki T, Taira N, Santarpia L, Doihara H, Gianni L, **Bianchini G**
ER + /HER2+ AND ER-/HER2+ BREAST CANCERS ARE MOLECULARLY DISTINCT BUT IMMUNE GENE SIGNATURES ARE PROGNOSTIC AND PREDICTIVE IN BOTH GROUPS
ESMO 2012, Vienna, (Abstract 1720)
- Gianni L, **Bianchini G**, Valagussa P, Belousov A, Thomas M, Ross G, Pusztai L
ADAPTIVE IMMUNE SYSTEM AND IMMUNE CHECKPOINTS ARE ASSOCIATED WITH RESPONSE TO PERTUZUMAB (P) AND TRASTUZUMAB (H) IN THE NEOSPHERE STUDY
35th Annual San Antonio Breast Cancer Symposium, 2012
- Karn T, Sanger N, Ruckhaberle E, **Bianchini G**, Muller V, Rody A, Solomayer EF, Fehm T, Holtrich U, Becker S
OPG AND PGR SHOW SIMILAR COHORT SPECIFIC EFFECTS AS PROGNOSTIC FACTORS IN ER POSITIVE BREAST CANCER
ESMO Ann Oncol. 2014 May;25 Suppl 1: i7
- Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, **Bianchini G**, Russo S, Ciruelos EV, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Maffei I, Valagussa P, Viale G
PATHOLOGIC COMPLETE RESPONSE (PCR) TO NEOADJUVANT TREATMENT WITH OR WITHOUT ATEZOLIZUMAB IN TRIPLE NEGATIVE, EARLY HIGH-RISK AND LOCALLY ADVANCED BREAST CANCER. NEOTRIPAPDL1 MICHELANGELO RANDOMIZED STUDY
42nd Annual San Antonio Breast Cancer Symposium, 2019
- Bianchini G**, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM et al:
LBA13 TUMOUR INFILTRATING LYMPHOCYTES (TILS), PD-L1 EXPRESSION AND THEIR DYNAMICS IN THE NEOTRIPAPDL1 TRIAL.
ESMO 2020 Annals of Oncology 2020, 31: S1145-S1146.
- Bianchini G**, Dugo M, Huang CS, Egle D, Bermejo B, Seitz RS, Nielsen TJJ, Zamagni C, Thill M, Anton A et al:
LBA12 PREDICTIVE VALUE OF GENE-EXPRESSION PROFILES (GEPS) AND THEIR DYNAMICS DURING THERAPY IN THE NEOTRIPAPDL1 TRIAL.
ESMO 2021 Annals of Oncology 2021, 32: S1283-S1284.
- Bianchini G**, Wang XQ, Danenberg E, Huang C-S, Egle D, Callari M, Bermejo B, Zamagni C, Thill M, Anton A et al:
ABSTRACT GS1-00: SINGLE-CELL SPATIAL ANALYSIS BY IMAGING MASS CYTOMETRY AND IMMUNOTHERAPY RESPONSE IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) IN THE NEOTRIPAPDL1 TRIAL.
SABCS 2021 Cancer Research 2022, 82(4_Supplement):GS1-00-GS01-00
- Bianchini G**, Malorni L, Arpino G, Zambelli A, Puglisi F, Mastro LD, Colleoni M, Montemurro F, Bianchi G, Paris I et al:
ABSTRACT GS3-07: CIRCULATING TUMOR DNA (CTDNA) DYNAMICS IN PATIENTS WITH HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) TREATED IN THE FIRST LINE WITH RIBOCICLIB (R) AND LETROZOLE (L) IN THE BIOLTALEE TRIAL
SABCS 2021 Cancer Research 2022, 82(4_Supplement):GS3-07

Arpino, G., **G. Bianchini**, L. Malorni, A. Zambelli, F. Puglisi, L. Del Mastro, M. Colleoni, F. Montemurro, G. V. Bianchi, I. Paris, G. Allegrini, S. Tamberi, M. E. Cazzaniga, M. Orditura, C. Zamagni, D. Grasso, M. Benelli, M. Callari, A. Benfante and M. De Laurentiis

CIRCULATING TUMOR DNA (CTDNA) AND SERUM THYMIDINE KINASE 1 ACTIVITY (TKA) MATCHED DYNAMICS IN PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC) TREATED IN FIRST-LINE (1L) WITH RIBOCICLIB (RIB) AND LETROZOLE (LET) IN THE BIOITALEE TRIAL

ASCO 2022 *Journal of Clinical Oncology* 40(16_suppl): 1012-1012

Hamilton, E. P., V. P. H. Bragaia, W. Yeo, S.-B. Kim, **G. Bianchini**, T. Yamashita, K. Yonemori, K. Inoue, G. Curigliano, S. A. Hurvitz, J. Cortes, H. Iwata, J. Cathcart, Y. Liu, C. C. Lee, E. Bako, R. Kim and S.-A. Im

TRASTUZUMAB DERUXTECAN (T-DXD) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN PATIENTS (PTS) WITH HER2-POSITIVE (HER2+) UNRESECTABLE AND/OR METASTATIC BREAST CANCER (MBC): SAFETY FOLLOW-UP OF THE RANDOMIZED, PHASE 3 STUDY DESTINY-BREAST03

ASCO 2022 *Journal of Clinical Oncology* 40(16_suppl): 1000

Poster discussions
(only first or last author)

First author: 7

Last author: 3

Bianchini G, Alvarez R, Qi Y, Hatzis C, Iwamoto T, Shiang CY, Coutant C, Symmans WF, Hortobagyi GN, Puztai L.

THE MOLECULAR ANATOMY OF BREAST CANCER STROMA; INDEPENDENT PROGNOSTIC ROLE IN ER-POSITIVE AND ER-NEGATIVE CANCERS

32nd Annual San Antonio Breast Cancer Symposium, 2009

Bianchini G, A. Prat, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, F. J. Vazquez Mazon, J. Baselga, L. Gianni

RESPONSE TO NEOADJUVANT TRASTUZUMAB AND CHEMOTHERAPY IN ER+ AND ER- HER2-POSITIVE BREAST CANCERS: GENE EXPRESSION ANALYSIS

Journal of Clinical Oncology, 2011 ASCO Annual Meeting Proceedings

Santarpia L, Iwamoto T, Di Leo A, Hayashi N, Stampfer M, Guarducci C, Symmans WF, Hortobagyi GN, Puztai L, **Bianchini G**

DNA REPAIR METAGENE SIGNATURE AS PROGNOSTIC AND PREDICTIVE FACTOR IN MOLECULAR BREAST CANCER SUBTYPES

Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings

Bianchini G, Cappelletti V, Callari M, Carcangiu ML, Eiermann W, Semiglazov V, Guillem V, Lluch A, Mansutti M, Zambetti M, Mariani G, Magazzu D, Valagussa P, Paolini B, Musella V, Di Buduo E, Miodini P, Scuro M, Daidone MG, Gianni L

PROLIFERATION-, ESTROGEN-, AND T-CELL-RELATED METAGENES TO PREDICT OUTCOME AFTER ADJUVANT/NEOADJUVANT CHEMOTHERAPY FOR OPERABLE BREAST CANCER IN THE ECTO TRIAL

Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition)

Bianchini G, Rossi G, Callari M, Iwamoto T, Galeota E, Karn T, Kelly MG, Zambetti M, Santarpia L, Puztai L, Gianni L

AN IMMUNE-RELATED SIGNATURE FOR PREDICTION OF RISK OF LATE RECURRENCES BEYOND PROLIFERATION AND ER-RELATED GENES IN ER-POSITIVE BREAST CANCER

Journal of Clinical Oncology, 2014 ASCO Annual Meeting Proceedings

Bianchini G, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Semiglazov V, Haba-Rodriguez Jdl, Oh D-Y, Poirier B, Pedrini JL, Valagussa P, Gianni L

RESIDUAL DISEASE AFTER HER2-DIRECTED THERAPIES IN THE NEOSPHERE STUDY: MODULATION OF TUMOR LYMPHOCYTE INFILTRATION (TIL) AND PROGNOSIS

Journal of Clinical Oncology, 2016 ASCO Annual Meeting Proceedings

Bianchini G; J Parker; L Carey; C M Perou; L Sica; A Prat; T Pieńkowski; Y-H Im; **G V Bianchi**; T Ling-Ming; M-C Liu; A Lluch; V Semiglazov; J de la Haba-Rodriguez; D-Y Oh; B Poirier; J L Pedrini; P Valagussa; L Gianni

RESEARCH-BASED PAM50 PREDICTS RISK OF RELAPSE IN RESIDUAL DISEASE AFTER ANTI-HER2 THERAPIES

ESMO 2018 Annals of Oncology, Volume 29, Issue suppl_8, October 2018

Bianchini G, Smart C, Mansutti M, Anton A, Licata L, Sassi I, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Lahuerta A, Zucchinelli P, Doglioni C, Viale G, Valagussa P, Tusquets I, Gianni L

CLINICAL IMPLICATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) IN THE ETNA STUDY

42nd Annual San Antonio Breast Cancer Symposium, 2019

Callari M, Barreca M, Dugo M, Galbardi B, Viganò L, Locatelli A, Licata L, Viale G, Valagussa P, Viale G, Gianni L, **Bianchini G**

ABSTRACT PD10-09: COMPARISON OF EARLY MODULATION OF BIOLOGICAL PATHWAYS AND IMMUNE MICROENVIRONMENT BY ANTHRACYCLINES- OR TAXANE-BASED TREATMENT

45th Annual San Antonio Breast Cancer Symposium, 2021

Dugo M, Huang C-S, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Anton A, Russo S, E. M. Ciruelos, B. L. Schweitzer, D. T. Ross, B. Galbardi, R. Greil, V. Semiglazov, B. Gyorffy, M. Colleoni, C. Kelly, G. Mariani, L. D. Mastro, P. Valagussa, G. Viale, M. Callari, L. Gianni, **G. Bianchini**

ABSTRACT PD10-06: PREDICTIVE VALUE OF RT-QPCR 27-GENE IO SCORE AND COMPARISON WITH RNA-SEQ IO SCORE IN THE NEOTRIPAPDL1 TRIAL.

45th Annual San Antonio Breast Cancer Symposium, 2021

Poster presentations

First author: 17

Second author: 5

Last author: 5

Bianchini G, Zambetti M, Pusztai L, Carcangiu M, Valagussa P, Gianni L
ESTROGEN RECEPTOR (ER) EXPRESSION BY QUANTITATIVE RT-PCR IDENTIFIES AN ER NEGATIVE SUBGROUP BY IHC WHO MIGHT BENEFIT FROM HORMONAL THERAPY
2007 ASCO Breast Annual Meeting

Bianchini G, Zambetti M, Mariani P, Moliterni A, Bianchi G, Mariani G, Fasolo A, Carcangiu ML, Valagussa P, Gianni L.

RECURRENCE SCORE BY ONCOTYPE DX EVALUATED ON THE PRIMARY BREAST TUMOR PREDICTS THE 2-YEAR SURVIVAL AFTER FIRST RELAPSE

30th Annual San Antonio Breast Cancer Symposium, 2007

Bianchini G, Zhao Y, Zambetti M, Pusztai L, Mariani M, Carcangiu ML, Valagussa P, Gianni L, Simon R
CROSS-PLATFORM PERFORMANCE OF GENES PREDICTIVE OF PATHOLOGIC RESPONSE TO DOXORUBICIN-PACLITAXEL CONTAINING REGIMENS

2008 ASCO Annual Meeting

Simon R, **Bianchini G**, Zambetti M, Govi S, Mariani G, Carcangiu ML, Valagussa P, Gianni L.
OUTCOME PREDICTION IN ESTROGEN-RECEPTOR POSITIVE, CHEMOTHERAPY AND TAMOXIFEN TREATED PATIENTS WITH LOCALLY ADVANCED BREAST CANCER

2008 ASCO Annual Meeting

Zambetti M, **Bianchini G**, Bianchi G, Mariani G, Moliterni A, Mariani P, De Benedictis E, Valagussa P, Greco M, Gianni L.

CLINICAL IMPACT OF PATHOLOGICAL AXILLARY DOWNSTAGING IN LOCALLY ADVANCED BREAST CANCER (LABC) AFTER PRIMARY SYSTEMIC CHEMOTHERAPY (PSC)

31st Annual San Antonio Breast Cancer Symposium, 2008

Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Valero V, Hortobagyi GN, Symmans WF, Pusztai L.

PROGNOSTIC AND THERAPEUTIC IMPLICATIONS OF KINASE EXPRESSION PATTERNS IN BREAST CANCER

2009 ASCO Breast Cancer Symposium

Coutant C, Rouzier R, Qi Y, Lehmann-Che J, **Bianchini G**, Iwamoto T, Hortobagyi GN, Symmans WF, Uzan S, Andre F, de The H, Pusztai L

CLINICAL SUBTYPE-DERIVED P53 GENE SIGNATURE IS PREDICTIVE OF PROGNOSIS AND RESPONSE TO CHEMOTHERAPY IN ER-POSITIVE BUT NOT IN ER-NEGATIVE BREAST CANCERS

32nd Annual San Antonio Breast Cancer Symposium, 2009

Iwamoto T, **Bianchini G**, Coutant C, Shiang CY, Symmans WF, Hortobagyi GN, Simon R, Pusztai L.
DIFFERENT BIOLOGICAL PROCESSES ARE ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN THE DIFFERENT MOLECULAR SUBTYPES OF BREAST CANCER

32nd Annual San Antonio Breast Cancer Symposium, 2009

Alvarez RH, **Bianchini G**, Hsu L, Cristofanilli M, Esteva FJ, Pusztai L, Buzdar A, Hortobagyi GN, Valero
THE EFFECT OF DIFFERENT SEQUENCING REGIMENS OF TAXANES AND ANTHRACYCLINES IN THE PRIMARY SYSTEMIC TREATMENT (PST) OF BREAST CANCER (BC) PATIENTS (PTS): M. D. ANDERSON CANCER CENTER RETROSPECTIVE ANALYSIS

2010 ASCO Annual Meeting

Alvarez RH, **Bianchini G**, Hsu L, Cristofanilli M, Esteva FJ, Pusztai L, Buzdar AU, Hortobagyi GN, Valero
CLINICAL OUTCOME OF TWO SEQUENCES OF ADMINISTERING PACLITAXEL (P) AND ANTHRACYCLINES (A) AS PRIMARY SYSTEMIC THERAPY (PST) AND ADJUVANT CHEMOTHERAPY (ACT) IN BREAST CANCER (BC) PATIENTS: A RETROSPECTIVE ANALYSIS FROM THE M. D. ANDERSON CANCER CENTER (MDACC)

33rd Annual San Antonio Breast Cancer Symposium, 2010

Gomez Pardo P, Prat A, **Bianchini G**, Pickl M, Belousov A, Koehler A, Semiglazov V, Eiermann W, Tjulandin S, Biakhov M, Lluch A, Zambetti M, Vázquez-Mazón F, Gianni L, Baselga J
PAM50 INTRINSIC SUBTYPING AND PATHOLOGIC RESPONSES TO NEOADJUVANT TRASTUZUMAB-BASED CHEMOTHERAPY IN HER2-POSITIVE BREAST CANCER
2011 ASCO Annual Meeting (J Clin Oncol 29 : 2011 (suppl; abstr 554))

Bianchini G, Pusztai L, Qi Y, Iwamoto T, Kelly CM, Zambetti M, Symmans WF, Gianni L.
A DENDRITIC METAGENE THAT PREDICTS GOOD PROGNOSIS BUT ENDOCRINE RESISTANCE IN BREAST CANCER
2012 ASCO Annual Meeting

Bianchini G, Pusztai L, Kelly CM, Iwamoto T, Callari M, Symmans WF, Gianni L.
CLINICAL IMPLICATIONS OF MOLECULAR HETEROGENEITY IN HIGHLY PROLIFERATIVE, ER-POSITIVE, HER2-NEGATIVE BREAST CANCER
35th Annual San Antonio Breast Cancer Symposium, 2012

Bianchini G, Rossi CM, Iwamoto T, Karn T, Callari M, Kelly CM, Pusztai L, Gianni L
EXPRESSION OF IMMUNE CHECKPOINT RELATED GENES ARE PROGNOSTIC IN UNTREATED BREAST CANCER
36th Annual San Antonio Breast Cancer Symposium, 2013

Bianchini G, Galeota E, Jiang T, Callari M, Zambetti M, Iwamoto T, Karn T, Hatzis C, Pusztai L, Gianni L
THE HETEROGENEOUS CLINICAL BEHAVIOR OF LUMINAL BREAST CANCERS IS ASSOCIATED WITH DIFFERENT MUTATIONAL LANDSCAPES
37th Annual San Antonio Breast Cancer Symposium, 2014

Ogiya R, Kumaki N, **Bianchini G**, Iwamoto T, Hayashi N, Tanaka T, Niikura N, Tokuda Y
COMPARISON OF TUMOR-INFILTRATING LYMPHOCYTES BETWEEN PRIMARY AND METASTATIC TUMORS IN BREAST CANCER PATIENTS
2015 ASCO Annual Meeting (Abstract 11021)

Bianchini G, Callari M, Iwamoto T, Riba M, Vigano' L, Locatelli A, Zambetti M, Karn T, Pusztai L, Gianni L
CONTRIBUTION OF IMMUNE SYSTEM AND TUMOR-RELATED INTERFERON SIGNALING TO EPIRUBICIN RESPONSE IN TRIPLE-NEGATIVE (TN) BREAST CANCERS
2015 ASCO Annual Meeting (Abstract 1081)

Bianchini G, Riba M, Zambelli S, Safonov A, Ogiya R, Jiang T, Hatzis C, Niikura N, Zambetti M, Iwamoto T, Pusztai L, Gianni L
TRIPLE-NEGATIVE (TN) AND HER2+ BREAST CANCERS (BC) HAVE DIFFERENT IMMUNE MILIEU IN PRIMARY AND METASTATIC TUMORS
38th Annual San Antonio Breast Cancer Symposium, 2015

Bianchini G, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, de la Haba-Rodríguez J, Semiglazov V, Oh D-Y, Poirier B, Pedrini JL, Valagussa P, Gianni L
PROLIFERATION AND P21 REFINE RISK OF RELAPSE IN RESIDUAL DISEASE AFTER HER2-DIRECTED THERAPIES
39th Annual San Antonio Breast Cancer Symposium, 2016

Gyorffy B, Nagy A, Pongor L, Locatelli A, Vigano' L, Safonov AM, Pusztai L, Gianni L, **Bianchini G**
EFFECT OF DNA HYPERMETHYLATION ON IMMUNE ESCAPE THROUGH DOWNREGULATION OF ANTIGEN PRESENTATION GENES IN BREAST CANCER
2016 ASCO Annual Meeting (Journal of Clinical Oncology 34(15_suppl): 11547-11547)

Bianchini G, Smart C, Bisagni G, Colleoni M, Mansutti M, Zamagni C, Del Mastro L, Zambelli S, Licata L, Frassoldati A, Viale G, Valagussa P, Gianni G
CLINICAL IMPLICATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) IN THE ETNA STUDY
42nd Annual San Antonio Breast Cancer Symposium, 2019

Licata L, Galbardi B, Gyoffry B, Karn T, Gianni L, **Bianchini G**
MOLECULAR DIFFERENCES BETWEEN HIGH AND LOW TUMOR MUTATIONAL BURDEN (TMB) ACROSS BREAST CANCER (BC) SUBTYPES
42nd Annual San Antonio Breast Cancer Symposium, 2019

Zambelli S, Smart C, **Bianchini G**, Mansutti M, Anton A, Licata L, Sassi I, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Lahuerta A, Zucchinelli P, Doglioni C, Viale G, Valagussa P, Tusquets I, Gianni L, Bernardi R

PROGNOSTIC AND PREDICTIVE VALUE OF PML IN THE ETNA STUDY AND THE TCGA

42nd Annual San Antonio Breast Cancer Symposium, 2019

De Laurentiis M, Malorni L, **Bianchini G**, Caputo C, Giuliano M, Zambelli A, Puglisi F, Del Mastro L, Colleoni M, Montemurro F, Bianchi G, Paris I, Allegrini G, Amaducci L, Cazzaniga ME, Orditura M, Zamagni C, Adamo V, Guarneri V, Battelli N, Valerio MR, Cinieri S, Bianchetti S, Grasso D, Castelletti D, Valsecchi D, Cotroneo E, Arpino G.

BIOITALEE - BIOMARKER ANALYSIS ON LIQUID BIOPSIES OF PATIENTS TREATED WITH RIBOCICLIB AND LETROZOLE AS FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER (ABC) (NCT03439046)

42nd Annual San Antonio Breast Cancer Symposium, 2019

Bianchini G, C. Smart, G. Bisagni, M. Colleoni, M. Mansutti, C. Zamagni, L. D. Mastro, S. Zambelli, L. Licata, A. Frassoldati, G. Viale, P. Valagussa and L. Gianni MODULATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) BY PALBOCICLIB, TRASTUZUMAB, PERTUZUMAB +/- FULVESTRANT IN ER+/HER2+ PATIENTS (PTS) ENROLLED IN THE MICHELANGELO NA-PHER2 TRIAL

SABCS 2019 Cancer Research 80(4_Supplement): P4-14-01

Licata, L., B. Galbardi, B. Györfy, T. Karn, L. Sica, A. Rognone, P. Zucchinelli, D. Aldrighetti, S. Zambelli, L. Gianni, **G. Bianchini**

MOLECULAR DIFFERENCES BETWEEN HIGH AND LOW TUMOR MUTATIONAL BURDEN (TMB) ACROSS BREAST CANCER (BC) SUBTYPES

SABCS 2019 Cancer Research 80(4_Supplement): P4-05-09

G. Bianchini, M. De Laurentiis, G. Arpino, A. Zambelli, F. Puglisi, L. Del Mastro, M.A. Colleoni, F. Montemurro, G.V. Bianchi, I. Paris, G. Allegrini, L. Amaducci, M.E. Cazzaniga, M. Orditura, C. Zamagni, S. Bianchetti, D. Castelletti, M. Benelli, M. Callari, L. Malorni

BIOITALEE: COMPARATIVE BIOMARKER ANALYSIS OF LIQUID BIOPSIES AND PAIRED TISSUE SAMPLES OF PATIENTS TREATED WITH RIBOCICLIB AND LETROZOLE AS FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER

ESMO Breast Cancer 2020

G. Bianchini, C. Smart, M. Mansutti, H.-J. Lück, S. Zambelli, C. Olier, A. Anton, G. Bisagni, L. Merlini, Murillo SM L. C. Martínez, J. I. Chacon, V. Semiglazov, M. Thill, A. Chan, I. Tusquets, L. Licata, P. Valagussa, G. Viale and L. Gianni.

MODULATION BY TREATMENT OF TUMOR INFILTRATING LYMPHOCYTES (TILS) AND PDL1 EXPRESSION IN TRIPLE-NEGATIVE BREAST CANCER IN THE ETNA TRIAL

ASCO 2020

Bianchini G, M. Dugo, B. Gyorffy, G. Bisagni, M. Colleoni, M. Mansutti, C. Zamagni, L. Del Mastro, S. Zambelli, A. Frassoldati, L. Licata, B. Galbardi, M. O. Biasi, L. Viganò, A. Locatelli, C. Smart, G. Viale, P. Valagussa, M. Callari and L. Gianni

ER AND IMMUNE-RELATED SIGNATURES DEFINE BENEFIT TO PALBOCICLIB, TRASTUZUMAB, PERTUZUMAB +/- FULVESTRANT IN ER+/HER2+ BREAST CANCER PATIENTS IN THE NA-PHER2 TRIAL

ASCO 2021 Journal of Clinical Oncology 39 (15_suppl): 555

Dugo M., Huang C.-S, D. Egle, B. Bermejo, C. Zamagni, R. S. Seitz, T. J. Nielsen, M. Thill, A. Anton, S. Russo, E. M. Ciruelos, B. L. Schweitzer, D. T. Ross, B. Galbardi, R. Greil, V. Semiglazov, B. Gyorffy, M. Colleoni, C. Kelly, G. Mariani, L. D. Mastro, P. Valagussa, G. Viale, M. Callari, L. Gianni and **G. Bianchini**

TRIPLE NEGATIVE BREAST CANCER SUBTYPES AND EARLY DYNAMICS OF THE 27-GENE IO SCORE PREDICT PCR IN THE NEOTRIPAPDL1 TRIAL

SABCS 2021 Cancer Research 82(4_Supplement): P2-07-12-P02-07-12

Callari, M., C.-S. Huang, D. Egle, B. Bermejo, C. Zamagni, M. Dugo, M. Thill, A. Anton, M. Barreca, S. Russo, E. M. Ciruelos, R. Greil, S. Zambelli, B. Gyorffy, C. Smart, O. Biasi, P. Valagussa, G. Viale, L. Gianni, **G. Bianchini**

IMMUNE MILIEU ASSOCIATED WITH PD-L1 STATUS IN TNBC IS DEPENDENT ON TIME OF BIOMARKER ASSESSMENT AND TREATMENT RECEIVED: A SECONDARY ANALYSIS OF THE NEOTRIPAPDL1 TRIAL

SABCS 2021 Cancer Research 82(4_Supplement): P1-04-02

**Invited presentation/discussion
at ESMO, ESMO Breast**

Bianchini G, Gianni L.

GENOMIC AND TRANSCRIPTOMIC CLASSIFIERS IN BREAST CANCER

Annals of Oncology 2007 18 (Supplement 9): ix157–ix158.

ESMO Conference Lugano (ECLU) 5 - 8 July

Bianchini G

Poster discussion

ESMO 2013

Bianchini G

Debate on controversy

Is trastuzumab single agent obsolete in early breast cancer? No

ESMO 2017

Bianchini G

Educational: Immunogram of breast cancer: identify predictive biomarkers responsible for immune checkpoint inhibitors

ESBO Breast Cancer Congress 2019 (Educational session)

Bianchini G

Oral presentation: Discussion LBA20, LBA21, 305O

ESMO 2019

Bianchini G

Educational: Selecting patients for immunotherapy – PDL1 and beyond

ESMO Breast Cancer Congress 2020

Bianchini G

Educational: Selecting patients for immunotherapy – PDL1 and beyond

ESMO Breast Cancer Congress 2023

Bianchini G

Highlights Metastatic Breast Cancer

ESMO 2024

Book Chapters

Principi di Medicina Interna “Rugarli”

Chapter: “**Carcinoma mammario**”

7th Edition

Principi di Medicina Interna “Rugarli”

Chapter: “**Carcinoma mammario**”

G. Bianchini, L. Licata, G. Viale

8th Edition

Metastatic Breast Cancer: Treatment and Management.

Capitolo “**Liquid biopsy in metastatic breast cancer**”.

G. Bianchini, L. Licata, G. Viale.

Edizion Minerva Medica [*in press*]

Clinical trial experience	Principal Investigator of more than 70 Phase II-III clinical trials in breast cancer Sub-investigator in more than 150 phase I-III clinical trials in breast cancer and other solid tumors
IDMC member	OPTimizing adjuvant prescription of PEMBROlizumab in patients with early-stage triple-negative breast cancer achieving pathologic complete response after standard neoadjuvant chemotherapy and pembrolizumab (OPT-PEMBRO) Phase 1b/2, Multicenter, Open-label, Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd monotherapy and combinations in Patients with inoperable advanced breast cancer (ABC) after progression on T-DXd (ICARUS BREAST02)
Trial and Translational Steering Committee Member	Member of 16 Steering Committees of international Phase III registration trials Co-chair Phase II trial SERAFA-1 (A Single arm, Open label, Multicentre, Phase IIIb Study of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients) Chair or Co-Chair of the following Translational Steering Committee of international trial - (Chair) Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer (ETNA) (NCT01822314) - (Chair) Neoadjuvant Therapy in TRIPlE Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1) (NCT02620280) - (Chair) Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo) (NCT03595592) - (Co-chair) A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) (NCT05629585) Member of the following Translational Steering Committee - CAMBRIA-1 Translational Advisory Committee Member - D8531C00002

Invited lectures	More than 350 invited lectures and talks at national and international meetings
Reviewer for journal	(from 2007 to 2026) The Lancet, Nature, Nature Medicine, Cell, Cancer cell, The Lancet Oncology, Annals of Oncology, Journal of Clinical Oncology, JAMA Oncology, Communications, Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, NPJ Breast Cancer, British Journal of Cancer, Molecular Oncology, Breast Cancer Research and Treatment, BMC cancer, European Journal of Cancer, Pathology, Current Cancer Drug Targets, Critical Reviews in Oncology/Hematology, Journal of Cancer, Investigational New Drugs, Journal of Cancer Research and Clinical Oncology, The Breast, Oncotarget
Reviewer for grants	For the Institute National du Cancer (France) For the Swiss Cancer League For the Fondation ARC pour la recherche sur le cancer (SIGN'IT Call for proposal 2018-2023) For the Fondation ARC pour la recherche sur le cancer (Cancer & Ageing Call for proposal 2021-2022) For the Fondation ARC pour la recherche sur le cancer (Pancreas) For the French National Cancer Institute 2023
Patents	'European Patent Application N. 12195182.6 and 12196177.5', titled "PDL-1 expression in anti-HER2 therapy" (co-inventor) Brevetto d'invenzione 102023000021825 avente titolo: Biomarcatori per predire una risposta a immunoterapia (co-inventor)
Past and present grants (only as Principal Investigator)	2007 Fondazione Michelangelo per l'Avanzamento della terapia e cura dei tumori (25.000 Eur for 1 year) 2012-2015 My First AIRC Grant (MFAG, 13428) 80.000 Euro/year for 3 years (Principal Investigator) Project Title "Prognostic and predictive role of the immune system in breast cancer" 2019-2023 Investigator Grant (IG, 21787) ~140.000 Euro/year for 5 years (Principal Investigator) (total 692.000 Euro) Project Title "Tailored administration of immune checkpoints inhibitors in TNBC and investigation of mechanisms of immune escape" 2020-2023 RF-2018-12367486 450.000 Euro in 3 years Project Title: "Development and validation of a predictor for clinical tailoring of neoadjuvant therapies in TNBC, including role and need for immune checkpoints inhibitors, and investigation of the mechanisms of primary and acquired immune resistance and escape to chemotherapy" 2023 Gilead Grant 30.000 Euro (Principal Investigator) Project Title "Espressione e significato clinico-biologico di TROP2 nel pancancer" 2025-2029 Investigator Grant (IG 2024 - ID. 30919 project) (≈800.000 Euro) (Principal Investigator) f from Fondazione AIRC per la ricerca sul cancro Title "Tackling resistance in high-risk triple-negative and HER2-positive breast cancers"
Teaching / Mentoring	10 Medical School Student MD Thesis Co-correlatore 4 Biology Student Thesis Co-correlatore 2 Resident Student (Internal Medicine) Thesis Co-correlatore 2 PhD Doctoral Student Thesis Co-correlatore Mentoring 5 MD Student in the Residency Oncology program

Membership

AIOM
ESMO
ASCO

Other professional/scientific roles

2009 – 2021 Scientific secretariat of "Fondazione Michelangelo"

2011 – today Scientific secretariat of the "Pathology Committee of Michelangelo"

2011 – 2013 Member of the European Alliance for Personalized Medicine board

2018 – today External Scientific Advisory Board Member for CIBERONC

2018 – today Advisory Board Member of the Scientific Committee of Fondation ARC pour la recherche sur le cancer

2018 – today Member of the Sign'It ad Hoc Committee (Fondation ARC pour la recherche sur le cancer)

2018 – today Member of the Scientific Ethical Committee of Fondazione Michelangelo

2020 - today Scientific Coordinator of Translational Researches of Fondazione Michelangelo

2021 – today Member of the Breast Cancer research Committee of Fondazione Michelangelo

2022 – today Member of the International Clinical Research Committee of Fondation ARC pour la recherche sur le cancer

2022 Member of the ESMO Breast Cancer Metastatic Track program selection 2023

2023 Member of the ESMO Breast Cancer Metastatic Track program selection 2024

2023 Member of the ECCO Therapeutic Track program selection 2024

Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali.

Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 GDPR 679/16 "Regolamento europeo sulla protezione dei dati personali" e del D.Lgs 101/2018"

Dichiaro di essere informato ai sensi e per gli effetti dell'art. 13 del D.lgs 196/2003, che il presente curriculum verrà allegato al programma dell'evento formativo e pubblicato nella banca dati presente nel sito <http://ecm.agenas.it>, e a tal fine presto il consenso al trattamento dei dati personali ivi contenuti

Date

10/07/2026

Signature